

1 **Omicron reactive multi protein specific CD4 T cells defines cellular immune response induced by**
2 **inactivated virus vaccines.**

3
4 Joey Ming Er Lim¹, Shou Kit Hang¹, Smrithi Hariharaputran¹, Adeline Chia¹, Nicole Tan¹, Eng Sing Lee^{2,3},
5 Edwin Chng⁴, Poh Lian Lim^{3,5,6}, Barnaby Young^{3,5,6}, David Chien Lye^{3,5,6,7}, Nina Le Bert¹, †Antonio
6 Bertoletti^{1,8}, †Anthony T Tan¹.

7 ¹Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

8 ²Clinical Research Unit, National Healthcare Group Polyclinics, Singapore

9 ³Lee Kong Chian School of Medicine, Singapore

10 ⁴Parkway Shenton Pte Ltd, Singapore

11 ⁵National Center of Infectious Diseases, Singapore

12 ⁶Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore

13 ⁷Yong Loo Lin School of Medicine, Singapore

14 ⁸Singapore Immunology Network, A*STAR, Singapore

15

16 †Corresponding authors

17

18

19 **Corresponding Authors and Lead Contact Information:**

20 Antonio BERTOLETTI, MD

21 Programme in Emerging Infectious Diseases

22 Duke-NUS Medical School

23 8 College Road

24 Singapore 169857

25 Singapore

26 Tel: +65 6601 2646

27 Email: antonio@duke-nus.edu.sg

28

29 Anthony Tanoto TAN, PhD

30 Programme in Emerging Infectious Diseases

31 Duke-NUS Medical School

32 8 College Road

33 Singapore 169857

34 Singapore

35 Email: Anthony.tan@duke-nus.edu.sg

36

37 **Total character count (45000 MAX with spaces)**

38 42233 (with spaces)

39

40 **Keywords**

41 COVID-19, inactivated vaccine, T cell response, adaptive immune response

1 **Summary**

2 Unlike mRNA vaccines based only on the Spike protein, inactivated SARS-CoV-2 vaccines should induce
3 a diversified T cell response recognizing distinct structural proteins. Here we performed a comparative
4 analysis of SARS-CoV-2 specific T cells in healthy individuals following vaccination with inactivated
5 SARS-CoV-2 or mRNA vaccines. Relative to Spike mRNA vaccination, inactivated vaccines elicited a
6 lower magnitude of Spike-specific T cells, but the combined Membrane, Nucleoprotein and Spike-
7 specific T cell response was quantitatively comparable to the sole Spike T cell response induced by
8 mRNA vaccines, and they efficiently tolerate the mutations characterizing the Omicron lineage.
9 However, this multi-protein specific T cell response was not mediated by a coordinated CD4 and CD8
10 T cell expansion but by selected priming of CD4 T cells. These findings can help in defining the role of
11 CD4 and CD8 T cells in the efficacy of the different vaccines to control severe COVID-19 after Omicron
12 infection.

13

1 Introduction

2 The availability of vaccines against SARS-CoV-2 have altered the landscape of the COVID-19 pandemic
3 and allowed the virus to persist among vaccinated populations. Globally, numerous SARS-CoV-2
4 vaccines have been developed, clinically trialled and administered till date¹ and vaccines based on
5 inactivated virus (Coronavac and Sinopharm) have been utilized in almost half of the 7.3 billion doses
6 that have been delivered to people worldwide before the end of 2021². Despite this staggering
7 number, a detailed analysis of cellular immune response elicited by inactivated vaccines in comparison
8 to mRNA or adenoviral based vaccines is still lacking. The reasons for the lack of a comparative analysis
9 of the components of the adaptive immunity responsible for killing virus-infected cells (virus-specific
10 CD8 T cells), aiding the production of high affinity antibodies (T follicular helper T cells) and sustaining
11 CD8 T cell function (Th1) are different³. Inactivated vaccines were utilized largely in China where
12 Western vaccines based on mRNA or adenoviral vectors were not available for a parallel comparison,
13 or in less wealthy nations that often lack research infrastructure to perform the complex
14 characterization of T cell response. Furthermore, the evaluation of the efficacy of different vaccines
15 were performed before the emergence of the antibody escaping Omicron variant¹, where clinical and
16 virological parameters, like the protection from infection or from symptomatic disease, were
17 associated with the quantity of neutralizing antibodies⁴. These comparative studies showed that the
18 quantity of neutralising antibodies stimulated by inactivated vaccines were ~10 times lower than that
19 induced by Spike mRNA vaccines and that significant waning of the antibodies occur approximately 3
20 months post-vaccination⁵⁻⁹, faster than the decline of antibodies observed with mRNA vaccines that
21 appears to persist at high levels for at least 6 months¹⁰⁻¹⁶.

22

23 These antibody response comparisons are however now obsolete since the evaluation of vaccination
24 efficacy against Omicron is now directed more towards understanding the ability of vaccines to protect
25 from disease and not infection¹⁷. Here, T cells are likely to play a more important role in light of their
26 ability to tolerate most of the amino acid variations present in Omicron and their ability to target virus
27 infected cells^{10,18,19}. In this regard, real world vaccine efficacy data showed that individuals vaccinated
28 with inactivated virus developed in general milder disease than non-vaccinated individuals²⁰⁻²³.
29 However, a direct comparative analysis of individuals vaccinated with inactivated SARS-CoV-2 and
30 mRNA vaccines showed relatively lowered protection from infection and severe disease against Delta
31 lineage in the former¹⁶, in line with a meta-analysis comparing the clinical efficacy of multiple COVID-
32 19 vaccines²⁴. These data suggest that inactivated vaccines might actually induce not only a weaker
33 humoral response towards Spike but also an impaired level of T cell response which was however not
34 experimentally supported. Analysis of SARS-CoV-2 specific T cells in individuals vaccinated with

1 inactivated virus demonstrated the induction of T cells specific for Spike and other structural proteins
2 (NP and Membrane)^{25,26} and a magnitude of vaccine-induced CD8 T cells that were superior to the
3 Spike-specific CD8 T cells induced by mRNA vaccines²⁶. Such strong induction of CD8 T cell response
4 was perplexing since the antigen processing and presentation pathway associated with an exogenous
5 protein antigen like inactivated SARS-CoV-2 vaccine is expected to induce primarily a CD4 T cell
6 response²⁷. Even though adjuvants can increase cross-presentation of viral antigen to CD8 T cells
7 mediated by a specialized population of dendritic cells²⁸, such processes should be less efficient than
8 the direct presentation of viral antigen by MHC-class I occurring in vaccine preparations where antigen
9 is endogenously synthesized within the cells, like in the case of mRNA based vaccines.

10

11 We therefore longitudinally analysed the vaccine-specific T cells induced in healthy individuals after
12 SARS-CoV-2 vaccination with inactivated or mRNA vaccines and characterized their ability to recognize
13 multiple proteins and the involvement of CD4 and CD8 T cells in such response. In addition, some of
14 the inactivated SARS-CoV-2 vaccinees received a homologous booster within the study period of 6
15 months. The effects of boosting on the vaccine-induced T cell response was also analysed together
16 with the evaluation of the effects of mutations present in the Omicron VOC on the vaccine-induced T
17 cell response against multiple viral proteins.

18

19

20

21

22

23

1 **Results**

2 **Magnitude of Spike-specific T cell response following vaccination with inactivated SARS-CoV-2** 3 **vaccines.**

4 Utilizing a pool of peptides covering the major immunodominant regions of the Spike protein (SpG
5 pool) in a whole blood cytokine release assay (CRA) that we have previously developed and validated
6 in mRNA vaccinated or infected individuals²⁹, we longitudinally analysed the magnitude of Spike-
7 specific T cell response following vaccination with inactivated SARS-CoV-2 vaccines in two cohorts
8 (Figure 1A; Table 1). The first cohort (Inactivated cohort) are healthy individuals who received two
9 doses of BBIBP inactivated vaccine (Sinopharm) given 21 days apart (n=30). The second cohort
10 (Heterologous cohort) are healthy individuals who first received a single dose of Spike mRNA vaccine
11 (Pfizer-BioNTech or Moderna) and developed adverse events that precludes the administration of the
12 second dose of mRNA vaccine. After the normalisation of the adverse events (1-6 months after
13 occurrence of adverse events), these individuals received two doses of CoronaVac inactivated vaccine
14 (Sinovac) given 21 days apart (n=20). A reference cohort (mRNA cohort) of healthy individuals who
15 received two doses of Spike mRNA vaccine (Pfizer-BioNTech or Moderna) were also analysed with the
16 whole blood CRA (n=79).

17

18 A single dose of inactivated vaccine induced an increase in Spike-induced IFN- γ and/or IL-2 in all
19 individuals of the Inactivated cohort 21 days post-vaccination (Figure 1B). In the Heterologous cohort,
20 Spike induced cytokine responses were already present before receiving inactivated vaccines due to
21 the prior dose of Spike mRNA vaccine, and the response remained high after inactivated SARS-CoV-2
22 vaccination (Figure 1B). The level of cytokines induced by the Spike peptide pool remained stable for
23 up to 2-3 months post-vaccination (1-2 months after receiving the second dose) in both cohorts
24 (Figure 1B). Even with the initial priming from mRNA vaccines prior to inactivated SARS-CoV-2
25 boosting, the peak magnitude of the Spike-induced cytokines detected in the Heterologous cohort do
26 not differ from the reference mRNA cohort (Figure 1B and 1C).

27

28 While the response kinetics appear similar between the Inactivated and mRNA cohorts, with peaks of
29 Spike-induced IFN- γ and IL-2 observed 21 days post-vaccination, the magnitude of the Spike-induced
30 response was lower in individuals who received inactivated vaccines than compared to those who had
31 Spike mRNA vaccination (Figure 1B and 1C). This difference was particularly significant 2-3 months
32 post-vaccination (Figure 1C). Even in the Heterologous cohort where individuals were primed with
33 Spike mRNA vaccine before boosting with inactivated vaccines, the magnitude of the Spike-induced T
34 cell cytokines was lower but did not reach statistical significance (Figure 1C). Analysis of the quantities

1 of IFN- γ and IL-2 secreted after SpG peptide pool stimulation did not show significant differences
2 between all 3 cohorts at 21 days or 2-3 months post-vaccination (Figure 1D).

3

4 These results shows that inactivated SARS-CoV-2 vaccines induced a quantitatively lower Spike-
5 specific T cell response with minimal differences in the balance of IFN- γ and IL-2 secreted in
6 comparison to mRNA vaccines. Consistent with what was observed previously²⁹, quantifying the Spike
7 T cell response through IL-2 secretion also appears more robust with less variability than by IFN- γ
8 secretion (Figure 1).

9

10 **Immunodominance of Spike-specific T cells induced by inactivated SARS-CoV-2 vaccines**

11 To understand the breadth of the Spike-specific T cell response induced by inactivated SARS-CoV-2
12 vaccines, we also performed the whole blood CRA assay using 7 overlapping peptide pools that spans
13 the entire Spike protein on blood collected 2-3 months after receiving inactivated or mRNA vaccines.
14 A schematic representation of the localization of peptide pools 1 to 7 in relation to the S1 (N-terminal),
15 RBD and S2 (C-terminal) regions of Spike is displayed in Figure 2A. Randomly selected individuals from
16 the Inactivated (n=5) and Heterologous (n=8) cohorts were analysed and we detected Spike T cell
17 responses in all individuals (Figure 2B). Almost all of the tested individuals had dominant Spike-specific
18 T cell response targeting the S2 chain of the Spike protein (Spike pool 5-7) (Figure 2B and 2C), with the
19 strongest response targeting pool 6 that covers amino acid 886-1085 of the Spike protein. There were
20 no observable differences between the cohorts and this immunodominance pattern is similar to that
21 observed in a previous study on mRNA vaccinated individuals (Figure 2B, mRNA n=6) where majority
22 of the Spike-specific T cells were targeting epitopes present in the S2 chain of Spike²⁹.

23

24 **Inactivated vaccine-induced T cell responses targeting multiple viral structural proteins**

25 The breadth of inactivated SARS-CoV-2 vaccine-induced T cell response should extend beyond the
26 Spike protein since the inactivated vaccine contains other structural proteins in addition to Spike^{30,31}.
27 Similar to the analysis of Spike-specific T cell response, we used overlapping peptides covering the
28 entire Membrane and Nucleoprotein in a whole blood CRA. We observed induction of Membrane-
29 (Figure 3A) and Nucleoprotein-specific (Figure 3B) T cell response in both cohorts. Over 90% of the
30 individuals in both cohorts had detectable Membrane- and Nucleoprotein-specific T cell response 21
31 days after vaccination, and the response persisted for at least 2-3 months post-vaccination (Figure 3A
32 and 3B). Secretion of IL-2 was again more robust with less variability among the individuals.
33 Importantly, the magnitude of the Spike T cell response was positively correlated with both the
34 Membrane and Nucleoprotein T cell response (Figure 3C), demonstrating that these responses were

1 indeed induced and associated with inactivated SARS-CoV-2 vaccination. Comparative analysis of the
2 cytokine quantity induced by Spike, Membrane and Nucleoprotein peptide pools 2-3 months post-
3 vaccination, showed that the majority of the vaccine induced T cell response were targeting the Spike
4 protein, followed by Nucleoprotein and Membrane, a hierarchy proportional to the size of the
5 respective proteins (Figure 3D).

6

7 We also measured the global level of T cell response induced by inactivated SARS-CoV-2 and Spike
8 mRNA vaccines. The amount of IFN- γ or IL-2 secreted after stimulation with SpG, Membrane and
9 Nucleoprotein peptide pools in both inactivated (n=27) and Heterologous (n=18) vaccinated cohorts
10 were comparable to the one detected by SpG only in mRNA vaccine recipients (n=79) (Figure 4).

11

12 **Phenotype of vaccine-induced T cell responses against multiple viral proteins**

13 We next sought to determine whether the inactivated vaccine-induced T cell response were mediated
14 by helper CD4+ or cytotoxic CD8+ T cells. Two different methods were used: a classical analysis of
15 upregulation of T cell activation markers (AIM) on the CD4 (CD25+ OX40+ 41BB+) and CD8 (CD69+
16 41BB+) T cell subsets after PBMC stimulation with peptide megapools, or a depletion approach where
17 CD8 and CD4 T cells were removed from the PBMC before stimulation with the peptide indicated
18 megapools in an IFN- γ ELISPOT assay (Figure 5A).

19

20 The two methods yielded completely different results in terms of the composition of the peptide pools
21 responsive T cells. A significant upregulation of AIM on both CD4 and CD8 T cells upon Spike
22 stimulation was detected in all tested individuals from both Inactivated and mRNA cohorts (Figure 5C
23 and D). In contrast, using the depletion approach, we observed a clear CD4 centric Spike T cell
24 response induced by inactivated vaccines (Figure 5B). Spike-specific CD8 T cells were only observed
25 at very low quantities in 2 out of 12 individuals vaccinated with inactivated SARS-CoV-2, in contrast to
26 the Spike-specific CD4 T cells that were present in all individuals tested (Figure 5B). In addition, T cells
27 specific for Nucleoprotein and Membrane were also CD4 centric with no detectable response in the
28 CD8 enriched samples (Supplementary Figure 3). On the other hand, both CD4 and CD8 Spike-specific
29 T cells were induced by mRNA vaccines (Figure 5B).

30

31 **Effects of inactivated SARS-CoV-2 vaccine booster (third dose) on the T cell response**

32 Studies that follows individuals who received primary vaccination (2 doses) with inactivated SARS-
33 CoV-2 vaccines have reported a progressive waning of neutralizing antibody at 3 months with titres
34 almost reaching pre-vaccination levels at ~6 months⁶⁻⁸. This has prompted policy changes in Singapore

1 to recommend the inclusion of a third dose of inactivated SARS-CoV-2 into the primary vaccination
2 series 3 months after the administration of the second dose. While the additional dose of inactivated
3 SARS-CoV-2 vaccine have been shown to effectively recall the neutralizing antibody titres that have
4 declined substantially after the second dose⁷, little is known about its effects on the amplification of
5 vaccine-induced T cell responses. As such, we compared the vaccine-induced T cell response before
6 and after the third vaccine dose in the Inactivated and Heterologous cohorts using the whole blood
7 CRA with SpG, Membrane and Nucleoprotein peptide pools.

8

9 In the cohorts studied, a total of 18 individuals in the Inactivated cohort and 7 in the Heterologous
10 cohort were given the third vaccine dose 1-3 months and <1 month before blood collection at ~6-7
11 months after the first vaccination dose respectively (Figure 6A). 3 individuals in the Inactivated cohort
12 and 11 in the Heterologous cohort have not received the third dose of vaccine at the time of blood
13 collection and they were analysed as controls. None of the vaccinated individuals analyzed had a
14 known history of SARS-CoV-2 infection up until the last blood sample collection at ~6-7 months from
15 the first vaccination dose.

16

17 From the whole blood CRA, we did not observe an appreciable change in the amount of secreted IFN-
18 γ and IL-2 after SpG peptide pool stimulation of whole blood samples collected before (~1-2 months
19 after the 2nd dose) and after (either 1-3 months or <1 month after the 3rd dose) the third dose of
20 inactivated SARS-CoV-2 vaccine in both Inactivated and Heterologous cohorts (Figure 6B). The
21 response towards Membrane and Nucleoprotein also remained unchanged before and after the third
22 vaccination dose (Figure 6C). Importantly, the magnitude of the whole blood CRA response against all
23 peptide pools tested did not differ between the individuals in either cohorts who received the third
24 inactivated vaccine dose and the controls who did not (Figure 6B and C).

25

26 Thus, the third dose of inactivated SARS-CoV-2 vaccine did not effectively induce a significant boost of
27 the vaccine-induced T cell response stimulated by the first two inactivated vaccine doses. Unlike the
28 neutralizing antibody titres that wanes within 3-6 months of the second dose⁶⁻⁸, the inactivated
29 vaccine-induced T cell response was maintained for at least 6 months without observable waning
30 (Figure 6B and C).

31

32 **Inactivated vaccine-induced T cell responses are largely preserved against the Omicron variant of**
33 **concern**

1 Given that the Omicron variant of concern (VOC) is the prevailing SARS-CoV-2 lineage circulating
2 globally, we determined whether the inactivated vaccine-induced T cell responses can recognise the
3 Omicron VOC proteins. We designed 3 sets of peptide pools specific for the Spike, Membrane and
4 Nucleoprotein respectively (Supplementary Table 1). Each set consist of a megapool made up of
5 overlapping peptides spanning the entire vaccine-derived protein, a WT pool containing peptides
6 covering the regions affected by mutations present in the Omicron variant of the protein, and a MT
7 pool consisting of peptides from the WT Pool with the amino acid mutations present in the Omicron
8 variant of the protein (Figure 7A). These peptide pools were used in the whole blood CRA using
9 samples collected from individuals in the Inactivated and Heterologous cohorts ~6-7 months after
10 their first inactivated vaccine dose. Only individuals who received the third inactivated vaccine dose
11 were analysed to ensure that the vaccine-induced T cell response was at its optimum.

12

13 We observed a wide heterogeneity in the ability of inactivated vaccine-induced T cell response to
14 recognise the Spike and Membrane proteins from the Omicron VOC, which ranges from the complete
15 abrogation to a gain of function exceeding the response towards the corresponding vaccine-derived
16 proteins (Figure 7B). Based on the amount of IFN- γ secreted in the whole blood CRA, 13/18 individuals
17 from the Inactivated cohort and 6/7 individuals from the Heterologous cohort have at least 50% of
18 their Spike-specific T cell response preserved against the Omicron Spike protein (Figure 7B). For the
19 Membrane-specific T cell response, at least 50% of the response was maintained in 10/18 individuals
20 from the Inactivated cohort and 2/7 individuals in the Heterologous cohort (Figure 7B). Interestingly,
21 almost all of the Nucleoprotein-specific T cell response was preserved with no individual exhibiting
22 lower than 80% of response against the Omicron Nucleoprotein (Figure 7B). This is in stark contrast
23 to the Membrane-specific T cell response even though both proteins have similar number of
24 mutations present in the Omicron VOC (Supplementary Table 1).

25

26 Combining the T cell response against multiple proteins, majority of the vaccinees still maintained
27 their response towards the Omicron VOC (Figure 7C). Importantly, in vaccinees where the singular
28 Spike-specific T cell response was significantly inhibited, the combined multi-antigenic T cell response
29 showed better preservation against Omicron (Figure 7C). Similar observations were made when the
30 amount of secreted IL-2 was analysed (Figure 7B and C).

31

32

33

1 **Discussion**

2 The virological landscape of the COVID-19 pandemic was radically modified by the emergence of new
3 SARS-CoV-2 lineages able to escape the neutralizing ability of antibodies elicited by vaccines based on
4 the Spike protein of the ancestor Wuhan isolates^{32,33}. This necessitates a more comprehensive analysis
5 of vaccine immunogenicity that could not only be based on antibody measurements but also requires
6 an evaluation of cellular immunity¹⁷. T cells are not playing a role in the prevention of infection but
7 can be extremely important in the control of the viral pathogenesis due to their ability to recognize
8 and lyse virus-infected cells and their association with viral control in acutely infected patients³⁴. For
9 this reason, we performed a detailed characterization of the cellular immunity specific for different
10 SARS-CoV-2 proteins elicited by inactivated virus vaccines and mRNA vaccines in a population of
11 healthy adult individuals.

12

13 Using a whole blood CRA²⁹ that measures the ability of T cells to secrete cytokines directly in whole
14 blood after encounter with specific antigens, we observed that the quantity of Spike peptide-
15 stimulated T cell cytokines were lower in vaccinees who received inactivated vaccines in comparison
16 to those who had Spike mRNA vaccines. However, both vaccine preparations induced a Th1 response
17 with similar IFN- γ and IL-2 secretion profile. Both vaccines also elicit a comparable Spike
18 immunodominance hierarchy focused more on the S2 region of Spike. (Figure 1 and 2). On the other
19 hand, inactivated vaccines do not elicit a response only focused on the Spike protein. Significant
20 quantities of Membrane and Nucleoprotein specific T cells were also induced after vaccination that
21 are clearly absent in individuals vaccinated with mRNA vaccines (Figure 3). A comparison of the multi-
22 antigenic vaccine-induced T cell response calculated by quantifying the levels of IFN- γ and IL-2 elicited
23 by inactivated versus mRNA vaccines showed that inactivated vaccines not only elicited a broader T
24 cell immunity but they also induce a quantitatively comparable T cell response against SARS-CoV-2
25 relative to mRNA vaccines (Figure 4).

26

27 The importance of eliciting a multi-antigenic T cell response against different SARS-CoV-2 proteins
28 should not be underestimated since T cell response in individuals who control SARS-CoV-2 with limited
29 or no symptoms possess T cell responses against different epitopes present in different structural and
30 non-structural proteins³⁴⁻³⁸. In addition, in experimental SARS-CoV-2 challenge of non-human
31 primates and mice vaccinated against Nucleoprotein^{39,40} or Envelope and Membrane⁴¹, the vaccinated
32 animals had less severe pathology and lower viral loads. This protective effect was associated with
33 the rapid recall of antigen-specific T cell responses without robust humoral immune response,
34 showing the protective capacity of T cells specific for other structural proteins of SARS-CoV-2³⁹⁻⁴¹. The

1 broad specificity is also potentially beneficial when considering the effects of amino acid mutations
2 present in the different SARS-CoV-2 proteins of known VOCs. While the inactivated SARS-CoV-2
3 vaccine induced T cell response was largely preserved against the Omicron VOC, there were
4 differences in the responses against different structural proteins (Figure 7). In all vaccinees tested,
5 Nucleoprotein-specific T cell responses were not affected by the mutations present in Omicron, while
6 both Spike and Membrane specific T cell responses were inhibited to various levels (Figure 7). This is
7 likely explained by the density of amino acid mutations present in each protein (Spike: 1 mutation in
8 40 amino acids; Membrane:1 in 67; Nucleoprotein: 1 in 80). A protein with a low density of amino
9 acid mutation is more likely to contain T cell epitopes that are fully conserved between the vaccine
10 strain and Omicron. Importantly, in vaccinees where their Spike-specific T cell response was
11 significantly inhibited by the mutations present in Omicron, their combined vaccine-induced T cell
12 response (Spike, Membrane and Nucleoprotein) was better preserved against Omicron (Figure 7C).
13 The presence of multi-protein specific T cells in individuals vaccinated with inactivated virus can
14 therefore provide them with a population of memory T cells more likely to tolerate the frequently
15 found amino acid substitutions in Spike which can partially suppress the Spike-specific T cell response
16 elicited by current Spike mRNA vaccines⁴²⁻⁴⁸. While the ability of Omicron to escape the full repertoire
17 of Spike-specific T cells induced by mRNA vaccines occurs only in a minority of individuals (10-15%),
18 immune escape can be substantial in particular for Spike-specific CD8 T cells⁴⁸.

19

20 However, the potential advantages of the heterogenous specificity of T cells generated by inactivated
21 SARS-CoV-2 vaccination needs to be balanced by our observation that inactivated vaccines do not
22 elicit any CD8 T cell response against any viral proteins. The robust vaccine-induced T cell response
23 was exclusively mediated in inactivated vaccine recipients by CD4 T cells. In contrast, individuals
24 vaccinated with mRNA and non-replicating adenoviral vectored Spike vaccines are capable of inducing
25 both CD4 and CD8 T cell responses as shown previously^{10,49-51}, and by our own data. Our results are
26 in contrast with previous observations by other groups that showed the ability of inactivated vaccines
27 to induce both CD4 and CD8 T cell response but are however in line with other data of T cell response
28 observed in other inactivated viral vaccines^{52,53}. The difference appears to be due to the different
29 method of analysis utilized by us and by the group in Hong-Kong²⁶. The AIM assay utilized by them
30 and by many groups worldwide (including us^{29,42,54}) is a powerful cellular technique that can define the
31 phenotype of peptide responsive T cells. It is equally well known that robust cytokine response of
32 peptide responsive T cells can also activate other T cells in the vicinity in a bystander fashion without
33 T cell receptor/epitope engagement⁵⁵⁻⁵⁷. From our comparative analysis of results obtained by AIM
34 and by depleting CD4 and CD8 T cells, it seems clear that a robust activation of CD8 T cells was

1 observed in inactivated vaccine recipients only with the AIM assay, showing that the results derived
2 from the AIM assay can be confounded, at least in vaccine recipients by robust bystander activation.

3

4 The combined impact of the multi-protein specific T cell response and its association with a deficiency
5 of CD8 T cell induction on the protection from disease development is difficult to be measured. In
6 SARS-CoV-2 convalescent rhesus macaques with sub-protective antibody titres, depletion of CD8 T
7 cells partially abrogated the protective efficacy of natural immunity against viral challenge, showing
8 the anti-SARS-CoV-2 effects mediated directly by CD8 T cells⁵⁸. At the same time, the induction of CD4
9 T cells specific for the nucleoprotein of SARS-CoV in the nasal cavity of mice protected the animal from
10 lethal disease after infection with different Coronaviruses⁵⁹. This protective effect was mediated
11 through the secretion of IFN- γ and importantly, through the subsequent recruitment of virus-specific
12 CD8 T cells⁵⁹. Similarly, memory CD4 T cells also directly and indirectly mediate protective effects in
13 Influenza A virus infected mice³. Clinical analysis of the efficacy of inactivated vaccines in different
14 populations before the emergence of Omicron have shown that inactivated virus vaccines provided
15 protection against the development of severe COVID-19²⁰⁻²³ but with lower rates than the one
16 provided by mRNA vaccines. On the contrary, recent data from Hong-Kong measuring the efficacy
17 against mild and severe COVID-19 development in healthy adults infected with Omicron showed
18 similar efficacy of the two vaccine preparations after three doses⁶⁰. Perhaps the lack of the
19 coordinated activation of CD4 and CD8 T cells observed in inactivated virus vaccine recipients infected
20 with Wuhan or Delta strains of SARS-CoV-2 was then compensated by the protein multi-specificity
21 that better tolerate the mutations present in Omicron.

22

23 Finally, our work showed that boosting with the third dose of inactivated SARS-CoV-2 vaccine 3
24 months after the second dose did not modify the Spike, Membrane or Nucleoprotein T cell response
25 (Figure 5). The magnitude of the T cell response against the 3 different proteins were even comparable
26 to individuals who completed their primary vaccination 6 months before and did not receive their
27 booster vaccines within the study period. Our data are in line with what was observed in a phase 2
28 placebo-controlled trial of inactivated SARS-CoV-2 vaccine: the third dose of inactivated vaccine 2
29 months after completion of the primary vaccination course (2 doses) only modestly increased the
30 neutralising antibody levels⁷. It is plausible that the ineffective boosting is due to the neutralisation
31 of the administered inactivated SARS-CoV-2 by the antibodies generated from the primary vaccination
32 course leading to a decline in antigen availability to stimulate the immune system. This hypothesis
33 was supported by the observation in the same phase 2 clinical trial where the neutralising antibody
34 titres were significantly boosted and were 3-4 fold higher when the administration of the third vaccine

1 dose was delayed till 8 months (instead of 2 months) after completion of the primary vaccination⁷. It
2 was also observed that humoral and T cell response were both robustly induced when the booster
3 inactivated SARS-CoV-2 vaccine was given 5 months after the primary vaccination⁶¹. These results
4 certainly calls for the future evaluation of the immunogenicity of inactivated SARS-CoV-2 vaccine in a
5 setting where interference from existing virus-specific immune responses can occur.

6

7 In conclusion, we present here a detailed functional and quantitative evaluation of the T cell response
8 induced by inactivated virus vaccines in comparison to mRNA vaccines. We show that in sharp
9 contrast to the clear inferiority of the humoral immunogenicity, inactivated vaccines elicit a T cell
10 response of comparable magnitude and superior breath, relative to the mRNA vaccines, that persisted
11 for at least 6 months without need of further boosting. The ability to recognize different SARS-CoV-2
12 proteins, in particular Membrane and NP, allowed the T cell response induced by inactivated vaccines
13 to better tolerate the mutations present in Omicron compared to the Spike-focused mRNA vaccine
14 induced T cells. However, the robust SARS-CoV-2 T cell response was exclusively mediated by CD4 T
15 cells while CD8 T cell were not induced. Recent clinical data of vaccine efficacy in a large population
16 suggested that the theoretical defect caused by the biased induction of a single component of cellular
17 immunity by the inactivated vaccine could be balanced by the superior ability to tolerate amino acid
18 mutations present in Omicron. Such data will have to be analysed in a large clinical study where T cell
19 responses will be measured and will help to clarify the impact of virus-specific CD4 or CD8 T cells in
20 SARS-CoV-2 pathogenesis.

21

22

23

24

1 **Acknowledgments**

2 We would like to thank all clinical and nursing staff who provided care for the patients; all clinical trial
3 coordinators and staff for their invaluable assistance in coordinating patient recruitment.

4

5 **Author contributions**

6 A.T. Tan, N. Le Bert and A. Bertoletti designed the experiments; J.M.E. Lim, S.K. Hang, S.
7 Hariharaputran, A. Chia, and N. Tan performed the experiments; A.T. Tan, N. Le Bert and A. Bertoletti
8 analyzed and interpreted all the data; A.T. Tan prepared the figures and wrote the paper; A.T. Tan, N.
9 Le Bert, P. L. Lim, B. Young, D.C. Lye and A. Bertoletti reviewed and edited the manuscript; E. S. Lee,
10 E. Chng, P. L. Lim, B. Young and D.C. Lye designed the clinical trial, recruited all the patients and
11 provided the clinical samples; A.T. Tan, N. Le Bert and A. Bertoletti designed and coordinated the
12 study.

13

14 **Declaration of interest**

15 A.T. Tan, N. Le Bert and A. Bertoletti reported a patent for a method to monitor SARS-CoV-2-specific
16 T cells in biological samples pending. The other authors have declared that no conflict of interest
17 exists.

18

19 **Funding source**

20 This study is supported by the Singapore Ministry of Health's National Medical Research Council under
21 its COVID-19 Research Fund (COVID19RF3-0060, COVID19RF-001 and COVID19RF-008).

22

1 **Figure Legends**

2 **Figure 1. Lower quantities of Spike-specific T cells were induced following vaccination with**
3 **inactivated SARS-CoV-2 compared to Spike mRNA vaccines.** A) Schematic showing the different
4 groups of vaccinated individuals studied and the time points where SARS-CoV-2 specific T cells were
5 analysed. Healthy individuals were given two infusions of either inactivated SARS-CoV-2 vaccines
6 (Inactivated: n=30) or Spike mRNA vaccines (mRNA: n=79) spaced 21 days apart. In the third group
7 (Heterologous: n=20), healthy individuals were first given a single infusion of Spike mRNA vaccine,
8 followed by two infusions of inactivated SARS-CoV-2 vaccine spaced 21 days apart due to the
9 development of significant adverse events following mRNA vaccination. Blood collected at the
10 indicated time points were used to quantify SARS-CoV-2 specific T cells. B) Longitudinal IFN- γ and IL-
11 2 concentrations detected through whole blood CRA after stimulation with SpG peptide pool. Grey
12 shaded areas denote the positivity cut-off for the measured cytokines. Pie charts shows the
13 proportion of individuals with detectable SpG-reactive T cells at the different time points. C) Cross-
14 sectional comparison of median IFN- γ and IL-2 concentrations detected through whole blood CRA
15 after stimulation with SpG peptide pool. Differences were analysed with Kruskal-Wallis test and
16 multiple comparisons were adjusted with Dunn's multiple comparison test. Only significant adjusted
17 P values are shown (****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$). D) Dot plots shows the IFN-
18 γ and IL-2 concentrations detected through whole blood CRA after stimulation with SpG peptide pool
19 at the indicated time points. Each dot denotes a single individual. Individuals in the Inactivated cohort
20 (red dots) and the Heterologous cohort (green dots) were overlaid on the vaccinees from the mRNA
21 cohort (blue dots). A dashed line of identity was added for reference.

22

23 **Figure 2. Inactivated SARS-CoV-2 vaccine-induced Spike-specific T cells targets the S2 chain of the**
24 **spike protein.** A) Schematic representation of the 7 Spike-specific peptide pools containing 15-mer
25 overlapping peptides spanning the entire Spike protein. Pools 1-4 contain peptides from the signal
26 peptide and the S1 chain while pools 5-6 encompass the S2 chain together with the transmembrane
27 and cytoplasmic domains. B) The amount of IFN- γ and IL-2 secreted in the whole blood CRA in
28 response to overlapping peptides covering the entire Spike protein (total Spike-specific T cell
29 response) of all vaccinees 2-3 months after receiving inactivated (Inactivated: n=5; Heterologous: n=8)
30 or mRNA vaccines (mRNA: n=6) are shown in the blue heatmap. The red heatmap denotes the
31 proportion of Spike-specific T cell responses of each vaccinee targeting the different parts of the Spike
32 protein. C) Bars shows the median proportion of Spike-specific T cell responses targeting the different
33 parts of the Spike protein as assayed through IFN- γ and IL-2 whole blood CRA in the vaccinees from
34 the Inactivated (circles) and Heterologous (triangles) cohorts. Differences were analysed with Kruskal-

1 Wallis test and multiple comparisons were adjusted with Dunn's multiple comparison test. Only
2 significant adjusted P values are shown (****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$).

3

4 **Figure 3. T cell responses targeting Membrane and Nucleoprotein were expanded following**
5 **vaccination with inactivated SARS-CoV-2.** Longitudinal IFN- γ and IL-2 concentrations detected
6 through whole blood CRA of all vaccinees receiving inactivated SARS-CoV-2 vaccines (Inactivated:
7 n=30; Heterologous: n=20) after stimulation with overlapping peptides covering the entire Membrane
8 (A) and Nucleoprotein (B). Grey shaded areas denote the positivity cut-off for the measured cytokines.
9 Pie charts shows the proportion of individuals with detectable M- or NP- reactive T cells at the
10 different time points. C) Linear regression analysis of the T cell response against SpG peptide pool and
11 the Membrane (blue) or Nucleoprotein (red) as evaluated by the quantification of IFN- γ (top) or IL-2
12 (bottom) in peptide stimulated whole blood from vaccinees (Inactivated: n=30; Heterologous: n=20)
13 at all analysed time points. Dotted lines denote the 95% confidence interval. D) Total Spike-,
14 Membrane- and Nucleoprotein-specific T cell response detected through whole blood CRA (IFN- γ : top
15 or IL-2: bottom) of all vaccinees 2-3 months after receiving inactivated vaccines (Inactivated: n=28;
16 Heterologous: n=20). Bar graph insert shows the size (amino acid) of the indicated proteins.
17 Differences were analysed with Kruskal-Wallis test and multiple comparisons were adjusted with
18 Dunn's multiple comparison test. Only significant adjusted P values are shown (****: $P \leq 0.0001$; ***:
19 $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$).

20

21 **Figure 4. Total T cell response induced by inactivated SARS-CoV-2 and mRNA vaccines are**
22 **comparable.** Total vaccine-specific T cell response (Spike only for mRNA vaccine; Spike, Membrane
23 and Nucleoprotein for inactivated vaccines) detected through whole blood CRA (IFN- γ : left or IL-2:
24 right) of vaccinees 2-3 months after receiving the respective vaccines (mRNA: n=79; Inactivated: n=27;
25 Heterologous: n=18). Spike-specific T cell response were evaluated by stimulation with SpG peptide
26 pool, while overlapping peptide megapools covering the entire Membrane or Nucleoprotein were
27 used to quantify the respective protein-specific T cell response. Dotted lines denote the lower limit
28 of quantification (LLOD) for each of the measured cytokine. Differences were analysed with Kruskal-
29 Wallis test and multiple comparisons were adjusted with Dunn's multiple comparison test. Only
30 significant adjusted P values are shown (****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$).

31

32 **Figure 5. Inactivated SARS-CoV-2 vaccines stimulates primarily CD4 T-cell responses.** A) Schematic
33 illustrates the analysis of SARS-CoV-2 specific CD4 and CD8 T cells by IFN- γ ELISPOT and by the
34 detection of activation markers on CD4 (CD25+ OX40+ 41BB+) and CD8 (CD69+ 41BB+) T cells. PBMCs

1 collected from the 3 cohorts of vaccinees 2-3 months after vaccination (Inactivated: n=6; mRNA: n=6;
2 Heterologous: n=6) were either depleted of CD8 or CD4 T cells through negative selection before
3 stimulation with overlapping peptides covering the entire Spike for ELISPOT. Total PBMCs were also
4 analysed as a control. For the AIM assay, total PBMCs were stimulated with overlapping peptides
5 covering the entire Spike protein for 24 hours before flow cytometry analysis. B) Bars denote the IFN-
6 γ SFU quantified for each vaccinee after stimulating CD4-enriched (green), CD8 enriched (blue) or total
7 PBMCs (grey) with Spike overlapping peptides. Representative ELISPOT well images of the respective
8 peptide stimulated cell populations are shown. C) Flow cytometry analysis of activation marker
9 expression on CD4 and CD8 T cells from individuals in the Inactivated (n=6) and mRNA (n=6) cohort
10 before and after stimulation with overlapping peptides covering the entire Spike protein. Differences
11 were analysed with paired t-test and only significant P values are shown (****: $P \leq 0.0001$; ***:
12 $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$). D) Flow cytometry dot plots of CD4 and CD8 T cells from
13 representative individuals before and after Spike peptide stimulation are shown together with the
14 corresponding AIM+ frequencies among the total CD4 or CD8 T cells.

15

16 **Figure 6. Vaccine induced T cell responses were not boosted upon the third inactivated vaccine dose.**

17 A) Schematic showing the time points where a third dose of inactivated vaccine was given to
18 individuals in the Inactivated (n=18/30 boosted) and Heterologous (n=7/20 boosted) cohorts. Blood
19 was collected ~6-7 months after the first dose of inactivated vaccines, which corresponds to 1-3
20 months and <1 month after the booster dose for individuals in the Inactivated cohort and
21 Heterologous cohort respectively. SARS-CoV-2 specific T cells after the booster dose were quantified
22 as described previously (Figure 1 and 3) through whole blood CRA after stimulation with SpG,
23 Membrane and Nucleoprotein peptide pools. Individuals who did not received the booster dose were
24 analysed as controls. B) Longitudinal IFN- γ and IL-2 concentrations detected through whole blood CRA
25 after stimulation with SpG peptide pool in individuals before and after receiving the booster dose.
26 Grey shaded areas denote the positivity cut-off for the measured cytokines. C) Graph shows the
27 change in IFN- γ and IL-2 concentrations detected through whole blood CRA after stimulation with SpG,
28 Membrane and Nucleoprotein peptide pools before and after the booster dose (V4-V3
29 concentrations) in individuals from the Inactivated and Heterologous cohorts. Differences were
30 analysed with Kruskal-Wallis test and multiple comparisons were adjusted with Dunn's multiple
31 comparison test. Only significant adjusted P values are shown (****: $P \leq 0.0001$; ***: $P \leq 0.001$; **:
32 $P \leq 0.01$; *: $P \leq 0.05$).

33

1 **Figure 7. Inactivated SARS-CoV-2 vaccine-induced T cell response against the Omicron variant of**
2 **concern.** A) Schematic showing the concept behind the design of the peptide pools to assess the
3 inactivated SARS-CoV-2 vaccine-induced T cell response against the Spike, Membrane and
4 Nucleoprotein from the Omicron variant of concern. Orange regions refers to amino acid mutations
5 present in the Omicron variant relative to the vaccine-derived SARS-CoV-2. The respective Megapool
6 contains peptides covering the whole wildtype SARS-CoV-2 protein (Spike, Membrane or
7 Nucleoprotein). The respective WT Pool contains peptides, with the wildtype amino acid sequence,
8 covering the regions affected by mutations present in the Omicron variant of the protein. The
9 respective MT Pool contains peptides from the WT Pool with the amino acid mutations present in the
10 Omicron variant. The equation shows how the percentage preservation of the vaccine-induced T cell
11 response against the Spike, Membrane or Nucleoprotein from the Omicron variant of concern was
12 calculated. B) Inactivated SARS-CoV-2 vaccine-induced T cell response of individuals from the
13 Inactivated (n=18; dark blue) and Heterologous (n=7; light blue) cohorts were evaluated by whole
14 blood CRA using the peptide pools described in A. The percentage preservation of the vaccine-induced
15 T cell response against the Spike, Membrane and Nucleoprotein from the Omicron variant of concern
16 were calculated using IFN- γ (top) or IL-2 (bottom) concentrations from whole blood CRA and displayed
17 as bars. Bars that enter the green shaded areas refers to a gain of function response against the
18 Omicron variant of concern. C) The percentage preservation of the Spike (blue) and total inactivated
19 vaccine-induced T cell response (red; Spike, Membrane and Nucleoprotein) against the Omicron
20 variant of concern in vaccinees from both Inactivated and Heterologous cohorts were calculated using
21 IFN- γ (left) or IL-2 (right) concentrations from whole blood CRA and displayed as bars.

22

23 **Table 1. Demographics of vaccinees from the 3 study cohorts.**

24

25

26

1 **STAR Methods**

2 **Key resource table**

Reagent or Resource	Source	Identifier
Antibodies		
Anti-human IFN- γ coating antibody	Mabtech	Cat# 3420-3-1000; RRID: AB_907282
Anti-human IFN- γ biotin	Mabtech	Cat# 3420-6-1000; RRID: AB_907272
Brilliant Violet 605 anti-human CD3 Antibody	Biolegend	Cat# 317322; RRID: AB_2561911
Brilliant Violet 650 Mouse anti-human CD4 Antibody	BD Horizon™	Cat# 563875; RRID: AB_2744425
PE/Cyanine7 Mouse anti-human CD8 Antibody	BD Pharmingen™	Cat# 557746; RRID: AB_396852
V450 Mouse anti-human CD25 Antibody	BD Horizon™	Cat# 560355; RRID: AB_1645565
Alexa Fluor® 700 anti-human CD69 Antibody	Biolegend	Cat# 310922; RRID: AB_493775
PE anti-human CD134 (OX40) Antibody	Biolegend	Cat# 350004; RRID: AB_10645478
APC Mouse anti-human CD137 Antibody	BD Pharmingen™	Cat# 550890; RRID: AB_398477
Biological samples		
Blood from individuals who received SARS-CoV-2 vaccine	National Centre for Infectious Diseases	N/A
Chemicals, peptides, and recombinant proteins		
Ficoll-paque plus	Cytiva	Cat# 17144003
Zombie NIR Fixable Viability Kit	Biolegend	Cat# 423105
Streptavidin-ALP	Mabtech	Cat# 3310-10-1000
KPL BCIP/NBT Phosphatase substrate	SeraCare	Cat# 5420-0038
15-mer SARS-CoV-2 overlapping Spike, Nucleoprotein and Membrane peptides	Genscript	N/A
Critical commercial kit		
Ella multianalyte immunoassay	Protein simple	N/A
EasySep Human CD4 Positive Selection Kits II	Stemcell Technologies	Cat# 17852
EasySep Human CD8 Positive Selection Kits II	Stemcell Technologies	Cat# 17853
Deposited data		
No unique dataset was generated	N/A	N/A
Software and algorithms		
Graphpad Prism 9	Graphpad	https://www.graphpad.com/scientific-software/prism/
Immunospot software	Cellular Technology Limited	http://www.immunospot.com/ImmunoSpot-analyzers-software
Kaluza Analysis Software	Beckman Coulter	https://www.beckman.com/flow-cytometry/software/kaluza

3

4 **Resource availability**

5 *Lead contact*

1 Further information and requests for resources and reagents should be directed to and will be fulfilled
2 by the lead contacts, Anthony T Tan (anthony.tan@duke-nus.edu.sg) and Antonio Bertoletti
3 (antonio@duke-nus.edu.sg).

4

5 *Material availability*

6 This study did not generate new unique reagents.

7

8 *Data and code availability*

9 This study did not generate any unique datasets or new codes.

10

11 **Experimental model and subject details**

12 The study design and protocol for the COVID-19 PROTECT study group were assessed by National
13 Healthcare Group (NHG) Domain Specific Review Board (DSRB) and approved under study number
14 2012/00917. Written informed consent was obtained from all study participants in accordance with
15 the Declaration of Helsinki for Human Research.

16

17 3 cohorts of vaccinated healthy individuals were studied (Table 1). Vaccinated individuals were
18 between 22-69 years of age, healthy and with no history of SARS-CoV-2 infection. The first cohort
19 (Inactivated cohort) are healthy individuals who received two doses of BBIBP inactivated vaccine
20 (Sinopharm) given 21 days apart (n=30). The second cohort (Heterologous cohort) are healthy
21 individuals who developed adverse events after receiving a single dose of mRNA vaccine and
22 proceeded to switch to vaccination with two doses of CoronaVac inactivated vaccine (Sinovac) given
23 21 days apart (n=19). A reference cohort (mRNA cohort) of healthy individuals who received two
24 doses of Spike mRNA vaccine (Pfizer-BioNTech or Moderna) were also analysed (n=79). Blood samples
25 were collected before receiving inactivated vaccines (Inactivated and Heterologous cohort) or mRNA
26 vaccines (mRNA cohort), 21 days and 2-3 months post-vaccination (Figure 1A). Local policy changes
27 recommended the inclusion of a third dose of inactivated SARS-CoV-2 vaccines into the primary
28 vaccination series 3 months after the administration of the second dose. To assess the effects of this
29 booster dose of inactivated vaccines, blood samples of individuals from the inactivated and
30 heterologous cohort were also collected 6 months post-vaccination. A total of 18 individuals in the
31 Inactivated cohort and 7 in the Heterologous cohort were given the booster dose 1-3 months and <1
32 month before blood collection respectively.

33

34 **Method details**

1 *Peptides*

2 15-mer peptides that overlapped by 10 amino acids spanning the entire protein sequences of
3 Nucleoprotein, Membrane and Spike protein of SARS-CoV-2 were synthesized and pooled into mega-
4 pools. In addition, 55 Spike peptides covering the immunogenic regions of the SARS-CoV-2 spike
5 protein representing 40.5% of the whole Spike protein (SpG peptide pool) were also synthesized,
6 pooled and used to stimulate whole blood as described previously²⁹. To measure the T cell response
7 against the Omicron variant, two additional peptide pools were designed for each viral structural
8 protein (Membrane, Nucleoprotein and Spike). The two pools include peptides impacted by the
9 mutations in Omicron, with one consisting of ancestral-derived peptides and another consisting of
10 Omicron-derived peptides covering the same region. Details of all the peptides used are found in
11 Supplementary Tables 1-4.

12

13 *Whole blood cytokine release assay*

14 The whole blood cytokine release assay was performed as described previously²⁹. In brief, 320 μ l of
15 freshly drawn blood (drawn within 6 hours of venepuncture) were mixed with 80 μ l RPMI and
16 stimulated with the indicated SARS-CoV-2 Spike peptide pools (Supplementary Table 1) at 2 μ g/ml or
17 with DMSO as a control. After 16 hours of incubation, the culture supernatant (plasma) was collected
18 and stored at -30°C. Cytokine concentrations in the plasma were quantified using an ELLA machine
19 with microfluidic multiplex cartridges that measured IFN- γ and IL-2 according to the manufacturer's
20 protocol (Protein Simple). The levels of cytokines present in the plasma of DMSO controls were
21 subtracted from the corresponding peptide pool-stimulated samples. The positivity threshold was set
22 at 10x times the lower limit of quantification of each cytokine (IFN- γ = 1.7pg/ml; IL-2 = 5.4pg/ml) after
23 DMSO background subtraction.

24

25 *PBMC isolation*

26 Peripheral blood was collected from all individuals in heparin-containing tubes, and peripheral blood
27 mononuclear cells (PBMCs) from all collected blood samples were isolated by Ficoll-Paque density
28 gradient centrifugation. Isolated PBMCs were either analysed directly or cryopreserved in liquid
29 nitrogen until required.

30

31 *Depletion of CD4+ or CD8+ T cells*

32 CD4+ or CD8+ T cells were positively selected from freshly isolated PBMCs with EasySep Positive
33 Selection Kits II (Stemcell Technologies). After magnetic affinity cell sorting, flow through consisting

1 of CD4-enriched and CD8-enriched PBMCs were collected and used immediately for IFN- γ ELISPOT
2 assay.

3

4 *IFN- γ ELISPOT Assay*

5 The frequency of SARS-CoV-2 specific T cells was quantified as described previously²⁹. Briefly, ELISPOT
6 plates (Millipore Sigma) were coated with human IFN- γ antibody overnight at 4°C. 250,000 to 400,000
7 total, CD4-enriched or CD8-enriched PBMCs were seeded per well and stimulated for 18 hours with
8 the indicated peptide pools at 1 μ g/mL. The plates were then incubated with a human biotinylated
9 IFN- γ detection antibody, followed by streptavidin–alkaline phosphatase (streptavidin-AP) and
10 developed using the KPL BCIP/NBT phosphatase substrate (Seracare Life Sciences). To quantify the
11 peptide-specific responses, spots of the unstimulated wells were subtracted from the peptide-
12 stimulated wells, and the results were expressed as spot-forming cells (SFC) per 10⁶ PBMCs. Results
13 were excluded if negative control wells had more than 30 SFC/10⁶ PBMCs or if positive control wells
14 stimulated with PMA/ionomycin were negative.

15

16 *Activation-induced marker (AIM) assay*

17 Cryopreserved PBMCs were thawed and stimulated with 1 μ g/mL mega-pool Spike peptides or
18 equivalent amount of DMSO for 24 hours at 37°C. Cells were then washed in phosphate buffered
19 saline and stained with Zombie NIR Fixable Viability Kit (Biolegend) to exclude dead cells in the
20 analysis. The cells were next washed in FACS buffer with 2mM EDTA and surface markers were stained
21 with the surface markers, anti-CD3, anti-CD4, anti-CD8, anti-CD25, anti-CD69, anti-CD134 (OX40) and
22 anti-CD137 (4-1BB), diluted in FACS buffer for 30 minutes on ice. After two more washes in FACS
23 buffer, cells were resuspended in PBS prior to acquisition with Beckman Coulter CytoFLEX S analyser.

24

25 **Quantification and statistical analysis**

26 All statistical analyses were performed using GraphPad Prism, version 9 (GraphPad Software). Where
27 applicable, the statistical tests used and the definition of centre were indicated in the figure legends.
28 Statistical significance was defined as having a P-value of less than 0.05. In all instances, “n” refers to
29 the number of patients analysed.

30

31

32

1 **Supplemental Information**

2 **Supplementary Figure 1. Representative flow cytometry analysis of CD4 enriched, CD8 enriched and**
3 **total PBMCs.**

4

5 **Supplementary Figure 2. Phenotypic analysis of Spike-specific T cells induced by inactivated SARS-**
6 **CoV-2 vaccine.** PBMCs were isolated from whole blood of individuals in the inactivated cohort 2-3
7 months post-vaccination. The PBMCs were stimulated with the Spike mega-pool or left unstimulated
8 as a control, and the upregulation of T cell activation markers on the CD4 and CD8 T cell subsets were
9 quantified through flow cytometry. The frequency of AIM+ CD4 (CD25+ OX40+ 41BB+) and CD8
10 (CD69+ 41BB+) T cells before and after stimulation with Spike mega-pool (n=6) are shown in panel A
11 and B respectively. Differences were analysed with Mann Whitney test and only significant P values
12 are shown (****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$). Dot plots shows the AIM+ CD4 and
13 CD8 T cell frequencies before and after Spike mega-pool stimulation in a representative individual.

14

15 **Supplementary Figure 3. CD4 Membrane- and Nucleoprotein-specific T cells were induced after**
16 **vaccination with inactivated SARS-CoV-2.** PBMCs collected from the 2 cohorts of vaccinees 2-3
17 months after vaccination (Inactivated: n=6; Heterologous: n=4) were either depleted of CD8 or CD4 T
18 cells through negative selection before stimulation with overlapping peptides covering the entire
19 Membrane and Nucleoprotein for ELISPOT. Total PBMCs were also analysed as a control. Bars denote
20 the IFN- γ SFU quantified for each vaccinee after stimulating CD4-enriched (green), CD8 enriched (blue)
21 or total PBMCs (grey) with Membrane (top) or Nucleoprotein (bottom) overlapping peptides.
22 Representative ELISPOT well images of the respective peptide stimulated cell populations are shown.

23

24 **Supplementary Table 1. SARS-CoV-2 Spike-specific peptide sequence.**

25

26 **Supplementary Table 2. SARS-CoV-2 Membrane-specific peptide sequence.**

27

28 **Supplementary Table 3. SARS-CoV-2 Nucleoprotein-specific peptide sequence.**

29

30 **Supplementary Table 1. SARS-CoV-2 Omicron VOC peptide sequence.**

31

32

1 References

- 2 1. Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., Cravioto, A.,
3 Rees, H., Higgins, J.P.T., Boutron, I., et al. (2021). Considerations in boosting COVID-19 vaccine
4 immune responses. *Lancet* 398, 1377-1380. 10.1016/S0140-6736(21)02046-8.
- 5 2. Mallapaty, S. (2021). China's COVID vaccines have been crucial - now immunity is waning.
6 *Nature* 598, 398-399. 10.1038/d41586-021-02796-w.
- 7 3. McKinstry, K.K., Strutt, T.M., Kuang, Y., Brown, D.M., Sell, S., Dutton, R.W., and Swain, S.L.
8 (2012). Memory CD4+ T cells protect against influenza through multiple synergizing
9 mechanisms. *J Clin Invest* 122, 2847-2856. 10.1172/JCI63689.
- 10 4. Cromer, D., Steain, M., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Kent, S.J., Triccas,
11 J.A., Houry, D.S., and Davenport, M.P. (2022). Neutralising antibody titres as predictors of
12 protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet*
13 *Microbe* 3, e52-e61. 10.1016/S2666-5247(21)00267-6.
- 14 5. Jeewandara, C., Aberathna, I.S., Pushpakumara, P.D., Kamaladasa, A., Guruge, D., Wijesinghe,
15 A., Gunasekera, B., Tanussiya, S., Kuruppu, H., Ranasinghe, T., et al. (2021). Persistence of
16 immune responses to the Sinopharm/BBIBP-CorV vaccine. *Immunity, Inflammation and*
17 *Disease*. 10.1101/2021.10.14.21265030.
- 18 6. Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K.K., Wang, H., et
19 al. (2022). Waning immune responses against SARS-CoV-2 variants of concern among
20 vaccinees in Hong Kong. *EBioMedicine* 77, 103904. 10.1016/j.ebiom.2022.103904.
- 21 7. Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al.
22 (2022). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of
23 a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind,
24 randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis* 22, 483-495.
25 10.1016/S1473-3099(21)00681-2.
- 26 8. Zhang, H., Jia, Y., Ji, Y., Cong, X., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., et al. (2022).
27 Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients.
28 *Front Microbiol* 13, 816778. 10.3389/fmicb.2022.816778.
- 29 9. Lim, W.W., Mak, L., Leung, G.M., Cowling, B.J., and Peiris, M. (2021). Comparative
30 immunogenicity of mRNA and inactivated vaccines against COVID-19. *Lancet Microbe* 2, e423.
31 10.1016/S2666-5247(21)00177-4.
- 32 10. Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin, B.,
33 Phillips, E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces immunological T cell
34 memory able to cross-recognize variants from Alpha to Omicron. *Cell* 185, 847-859 e811.
35 10.1016/j.cell.2022.01.015.
- 36 11. Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M.,
37 Lundgreen, K.A., Reynaldi, A., Houry, D.S., Pattekar, A., et al. (2021). mRNA vaccines induce
38 durable immune memory to SARS-CoV-2 and variants of concern. *Science* 374, abm0829.
39 10.1126/science.abm0829.
- 40 12. Guerrero, G., Picozza, M., D'Orso, S., Placido, R., Pirronello, M., Verdiani, A., Termine, A.,
41 Fabrizio, C., Giannessi, F., Sambucci, M., et al. (2021). BNT162b2 vaccination induces durable
42 SARS-CoV-2-specific T cells with a stem cell memory phenotype. *Sci Immunol* 6, eabl5344.
43 10.1126/sciimmunol.abl5344.
- 44 13. Doria-Rose, N., Suthar, M.S., Makowski, M., O'Connell, S., McDermott, A.B., Flach, B.,
45 Ledgerwood, J.E., Mascola, J.R., Graham, B.S., Lin, B.C., et al. (2021). Antibody Persistence
46 through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl J Med*
47 384, 2259-2261. 10.1056/NEJMc2103916.
- 48 14. Pegu, A., O'Connell, S.E., Schmidt, S.D., O'Dell, S., Talana, C.A., Lai, L., Albert, J., Anderson, E.,
49 Bennett, H., Corbett, K.S., et al. (2021). Durability of mRNA-1273 vaccine-induced antibodies
50 against SARS-CoV-2 variants. *Science* 373, 1372-1377. 10.1126/science.abj4176.

- 1 15. Terpos, E., Karalis, V., Ntanasis-Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola,
2 M.S., Malandrakis, P., Gianniou, D.D., Kastritis, E., Trougkos, I.P., and Dimopoulos, M.A.
3 (2022). Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with
4 BNT162b2 and AZD1222. *Biomedicines* *10*. 10.3390/biomedicines10020338.
- 5 16. Premikha, M., Chiew, C.J., Wei, W.E., Leo, Y.S., Ong, B., Lye, D.C., Lee, V.J., and Tan, K.B. (2022).
6 Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19
7 Infection and Severe Disease in Singapore. *Clin Infect Dis*. 10.1093/cid/ciac288.
- 8 17. Vardhana, S., Baldo, L., Morice, W.G., 2nd, and Wherry, E.J. (2022). Understanding T cell
9 responses to COVID-19 is essential for informing public health strategies. *Sci Immunol* *7*,
10 eabo1303. 10.1126/sciimmunol.abo1303.
- 11 18. Geers, D., Shamier, M.C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N.N., Schmitz,
12 K.S., Rijsbergen, L.C., van Osch, J.A.T., Dijkhuizen, E., et al. (2021). SARS-CoV-2 variants of
13 concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors
14 and vaccinees. *Sci Immunol* *6*. 10.1126/sciimmunol.abj1750.
- 15 19. Tarke, A., Sidney, J., Methot, N., Yu, E.D., Zhang, Y., Dan, J.M., Goodwin, B., Rubiro, P.,
16 Sutherland, A., Wang, E., et al. (2021). Impact of SARS-CoV-2 variants on the total CD4(+) and
17 CD8(+) T cell reactivity in infected or vaccinated individuals. *Cell Rep Med* *2*, 100355.
18 10.1016/j.xcrm.2021.100355.
- 19 20. Jara, A., Undurraga, E.A., Gonzalez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo,
20 J., Leo, K., Leon, F., et al. (2021). Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
21 *N Engl J Med* *385*, 875-884. 10.1056/NEJMoa2107715.
- 22 21. Ranzani, O.T., Hitchings, M.D.T., Dorion, M., D'Agostini, T.L., de Paula, R.C., de Paula, O.F.P.,
23 Villela, E.F.M., Torres, M.S.S., de Oliveira, S.B., Schulz, W., et al. (2021). Effectiveness of the
24 CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in
25 Brazil: test negative case-control study. *BMJ* *374*, n2015. 10.1136/bmj.n2015.
- 26 22. Kang, M., Yi, Y., Li, Y., Sun, L., Deng, A., Hu, T., Zhang, J., Liu, J., Cheng, M., Xie, S., et al. (2022).
27 Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta)
28 Variant During an Outbreak in Guangdong, China : A Cohort Study. *Ann Intern Med* *175*, 533-
29 540. 10.7326/M21-3509.
- 30 23. Hu, Z., Tao, B., Li, Z., Song, Y., Yi, C., Li, J., Zhu, M., Yi, Y., Huang, P., and Wang, J. (2022).
31 Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta)
32 variant-infected patients in Jiangsu, China. *Int J Infect Dis* *116*, 204-209.
33 10.1016/j.ijid.2022.01.030.
- 34 24. Rotshild, V., Hirsh-Racah, B., Miskin, I., Muszkat, M., and Matok, I. (2021). Comparing the
35 clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. *Sci Rep*
36 *11*, 22777. 10.1038/s41598-021-02321-z.
- 37 25. Deng, Y., Li, Y., Yang, R., and Tan, W. (2021). SARS-CoV-2-specific T cell immunity to structural
38 proteins in inactivated COVID-19 vaccine recipients. *Cell Mol Immunol* *18*, 2040-2041.
39 10.1038/s41423-021-00730-8.
- 40 26. Lau, Y.-L., Duque, J.R., Wang, X., Leung, D., Cheng, S., Cohen, C., Mu, X., Hachim, A., Zhang, Y.,
41 Chan, S.-M., et al. (07 May 2022). Immunogenicity and reactogenicity of SARS-CoV-2 mRNA
42 and inactivated vaccines in healthy adolescents. PREPRINT (version 1) available at Research
43 Square [<https://doi.org/10.21203/rs.3.rs-1327020/v1>].
- 44 27. Pishesha, N., Harmand, T.J., and Ploegh, H.L. (2022). A guide to antigen processing and
45 presentation. *Nat Rev Immunol*. 10.1038/s41577-022-00707-2.
- 46 28. Ho, N.I., Huis In 't Veld, L.G.M., Raaijmakers, T.K., and Adema, G.J. (2018). Adjuvants Enhancing
47 Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? *Front Immunol* *9*,
48 2874. 10.3389/fimmu.2018.02874.
- 49 29. Tan, A.T., Lim, J.M., Le Bert, N., Kunasegaran, K., Chia, A., Qui, M.D., Tan, N., Chia, W.N., de
50 Alwis, R., Ying, D., et al. (2021). Rapid measurement of SARS-CoV-2 spike T cells in whole blood
51 from vaccinated and naturally infected individuals. *J Clin Invest* *131*. 10.1172/JCI152379.

- 1 30. Liu, C., Mendonca, L., Yang, Y., Gao, Y., Shen, C., Liu, J., Ni, T., Ju, B., Liu, C., Tang, X., et al.
2 (2020). The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-
3 EM and Cryo-ET. *Structure* 28, 1218-1224 e1214. 10.1016/j.str.2020.10.001.
- 4 31. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020).
5 Development of an inactivated vaccine candidate for SARS-CoV-2. *Science* 369, 77-81.
6 10.1126/science.abc1932.
- 7 32. Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M.,
8 Groves, N., O'Connell, A.M., et al. (2022). Covid-19 Vaccine Effectiveness against the Omicron
9 (B.1.1.529) Variant. *N Engl J Med* 386, 1532-1546. 10.1056/NEJMoa2119451.
- 10 33. Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland,
11 W.H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022). Considerable escape of SARS-CoV-2
12 Omicron to antibody neutralization. *Nature* 602, 671-675. 10.1038/s41586-021-04389-z.
- 13 34. Tan, A.T., Linster, M., Tan, C.W., Le Bert, N., Chia, W.N., Kunasegaran, K., Zhuang, Y., Tham,
14 C.Y.L., Chia, A., Smith, G.J.D., et al. (2021). Early induction of functional SARS-CoV-2-specific T
15 cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* 34,
16 108728. 10.1016/j.celrep.2021.108728.
- 17 35. Le Bert, N., Clapham, H.E., Tan, A.T., Chia, W.N., Tham, C.Y.L., Lim, J.M., Kunasegaran, K., Tan,
18 L.W.L., Dutertre, C.A., Shankar, N., et al. (2021). Highly functional virus-specific cellular
19 immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med* 218.
20 10.1084/jem.20202617.
- 21 36. Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Stralin, K., Gorin, J.B., Olsson, A., Llewellyn-
22 Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020). Robust T Cell Immunity in
23 Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell* 183, 158-168 e114.
24 10.1016/j.cell.2020.08.017.
- 25 37. Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 184,
26 861-880. 10.1016/j.cell.2021.01.007.
- 27 38. Ferretti, A.P., Kula, T., Wang, Y., Nguyen, D.M.V., Weinheimer, A., Dunlap, G.S., Xu, Q., Nabils,
28 N., Perullo, C.R., Cristofaro, A.W., et al. (2020). Unbiased Screens Show CD8(+) T Cells of
29 COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the
30 Spike Protein. *Immunity* 53, 1095-1107 e1093. 10.1016/j.immuni.2020.10.006.
- 31 39. Harris, P.E., Brasel, T., Massey, C., Herst, C.V., Burkholz, S., Lloyd, P., Blankenberg, T., Bey, T.M.,
32 Carback, R., Hodge, T., et al. (2021). A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid
33 Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. *Vaccines (Basel)* 9.
34 10.3390/vaccines9050520.
- 35 40. Matchett, W.E., Joag, V., Stolley, J.M., Shepherd, F.K., Quarnstrom, C.F., Mickelson, C.K.,
36 Wijeyesinghe, S., Soerens, A.G., Becker, S., Thiede, J.M., et al. (2021). Cutting Edge:
37 Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. *J Immunol*
38 207, 376-379. 10.4049/jimmunol.2100421.
- 39 41. Chen, J., Deng, Y., Huang, B., Han, D., Wang, W., Huang, M., Zhai, C., Zhao, Z., Yang, R., Zhao,
40 Y., et al. (2022). DNA Vaccines Expressing the Envelope and Membrane Proteins Provide
41 Partial Protection Against SARS-CoV-2 in Mice. *Front Immunol* 13, 827605.
42 10.3389/fimmu.2022.827605.
- 43 42. Qui, M., Le Bert, N., Chan, W.P.W., Tan, M., Hang, S.K., Hariharaputran, S., Sim, J.X.Y., Low,
44 J.G.H., Ng, W., Wan, W.Y., et al. (2022). Favorable vaccine-induced SARS-CoV-2 specific T cell
45 response profile in patients undergoing immune-modifying therapies. *J Clin Invest.*
46 10.1172/JCI159500.
- 47 43. Gao, Y., Cai, C., Grifoni, A., Muller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,
48 Osterborg, A., Bergman, P., et al. (2022). Ancestral SARS-CoV-2-specific T cells cross-recognize
49 the Omicron variant. *Nat Med* 28, 472-476. 10.1038/s41591-022-01700-x.

- 1 44. Jung, M.K., Jeong, S.D., Noh, J.Y., Kim, D.U., Jung, S., Song, J.Y., Jeong, H.W., Park, S.H., and
2 Shin, E.C. (2022). BNT162b2-induced memory T cells respond to the Omicron variant with
3 preserved polyfunctionality. *Nat Microbiol.* 10.1038/s41564-022-01123-x.
- 4 45. Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S.,
5 Bernstein, M., Karim, F., et al. (2022). T cell responses to SARS-CoV-2 spike cross-recognize
6 Omicron. *Nature* 603, 488-492. 10.1038/s41586-022-04460-3.
- 7 46. GeurtsvanKessel, C.H., Geers, D., Schmitz, K.S., Mykytyn, A.Z., Lamers, M.M., Bogers, S.,
8 Scherbeijn, S., Gommers, L., Sablerolles, R.S.G., Nieuwkoop, N.N., et al. (2022). Divergent
9 SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. *Sci*
10 *Immunol* 7, eabo2202. 10.1126/sciimmunol.abo2202.
- 11 47. Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K.,
12 Sciacca, M., VanWyk, H., Wu, C., et al. (2022). Vaccines elicit highly conserved cellular
13 immunity to SARS-CoV-2 Omicron. *Nature* 603, 493-496. 10.1038/s41586-022-04465-y.
- 14 48. Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., Tano-Menka,
15 R., Ofoman, O., Gayton, A., et al. (2022). T cell reactivity to the SARS-CoV-2 Omicron variant is
16 preserved in most but not all individuals. *Cell* 185, 1041-1051 e1046.
17 10.1016/j.cell.2022.01.029.
- 18 49. Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Galvez, R.I., Cortes, F.H.,
19 Grifoni, A., Tarke, A., Chang, J., et al. (2022). Humoral and cellular immune memory to four
20 COVID-19 vaccines. *bioRxiv*. 10.1101/2022.03.18.484953.
- 21 50. Munro, A.P.S., Janani, L., Cornelius, V., Aley, P.K., Babbage, G., Baxter, D., Bula, M., Cathie, K.,
22 Chatterjee, K., Dodd, K., et al. (2021). Safety and immunogenicity of seven COVID-19 vaccines
23 as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
24 (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 398, 2258-
25 2276. 10.1016/S0140-6736(21)02717-3.
- 26 51. Khoo, N.K.H., Lim, J.M.E., Gill, U.S., de Alwis, R., Tan, N., Toh, J.Z.N., Abbott, J.E., Usai, C., Ooi,
27 E.E., Low, J.G.H., et al. (2022). Differential immunogenicity of homologous versus
28 heterologous boost in Ad26.COV2.S vaccine recipients. *Med (N Y)* 3, 104-118 e104.
29 10.1016/j.medj.2021.12.004.
- 30 52. Skibinski, D.A.G., Jones, L.A., Zhu, Y.O., Xue, L.W., Au, B., Lee, B., Naim, A.N.M., Lee, A.,
31 Kaliaperumal, N., Low, J.G.H., et al. (2018). Induction of Human T-cell and Cytokine Responses
32 Following Vaccination with a Novel Influenza Vaccine. *Sci Rep* 8, 18007. 10.1038/s41598-018-
33 36703-7.
- 34 53. Wijaya, L., Tham, C.Y.L., Chan, Y.F.Z., Wong, A.W.L., Li, L.T., Wang, L.F., Bertoletti, A., and Low,
35 J.G. (2017). An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist
36 PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult
37 volunteers. *Vaccine* 35, 1175-1183. 10.1016/j.vaccine.2016.12.031.
- 38 54. Kalimuddin, S., Tham, C.Y.L., Qui, M., de Alwis, R., Sim, J.X.Y., Lim, J.M.E., Tan, H.C., Syenina,
39 A., Zhang, S.L., Le Bert, N., et al. (2021). Early T cell and binding antibody responses are
40 associated with COVID-19 RNA vaccine efficacy onset. *Med (N Y)* 2, 682-688 e684.
41 10.1016/j.medj.2021.04.003.
- 42 55. Seder, R.A., and Ahmed, R. (2003). Similarities and differences in CD4+ and CD8+ effector and
43 memory T cell generation. *Nat Immunol* 4, 835-842. 10.1038/ni969.
- 44 56. Kim, T.S., and Shin, E.C. (2019). The activation of bystander CD8(+) T cells and their roles in
45 viral infection. *Exp Mol Med* 51, 1-9. 10.1038/s12276-019-0316-1.
- 46 57. Lee, H.G., Cho, M.Z., and Choi, J.M. (2020). Bystander CD4(+) T cells: crossroads between
47 innate and adaptive immunity. *Exp Mol Med* 52, 1255-1263. 10.1038/s12276-020-00486-7.
- 48 58. McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J., Peter,
49 L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in rhesus
50 macaques. *Nature* 590, 630-634. 10.1038/s41586-020-03041-6.

- 1 59. Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K., Agnihothram,
2 S., Baric, R.S., David, C.S., and Perlman, S. (2016). Airway Memory CD4(+) T Cells Mediate
3 Protective Immunity against Emerging Respiratory Coronaviruses. *Immunity* 44, 1379-1391.
4 10.1016/j.immuni.2016.05.006.
- 5 60. McMenemy, M.E., Nealon, J., Lin, Y., Wong, J.Y., Cheung, J.K., Lau, E.H.Y., Wu, P., Leung, G.M.,
6 and Cowling, B.J. (2022). Vaccine effectiveness of two and three doses of BNT162b2 and
7 CoronaVac against COVID-19 in Hong Kong. medRxiv. 10.1101/2022.03.22.22272769
- 8 61. Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022).
9 Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2
10 vaccine. *Cell Discov* 8, 10. 10.1038/s41421-022-00373-7.

11

	Heterologous	Inactivated	mRNA
Characteristic	One dose of mRNA vaccine (BNT162b2 or mRNA-1273) followed by two doses of CoronaVac	Two doses of BBIBP-Corv, 21 days apart	Two doses of BNT162b2, 21 days apart
N	20	30	79
Age	Mean (range): 47.54 (22-69)	Mean (range): 48.7 (22-74)	Mean (range): 38.1 (22-60)
Sex	F: 14 M: 6	F: 16 M: 14	F: 55 M: 24
Race	Chinese: 18 Malay: 2	Chinese: 26 Indian: 1 Malay: 1 Others: 2	Chinese: 42 Indian: 7 Malay: 10 Others: 20

Table 1. Demographics of vaccinees from the 3 study cohorts.

A

medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275616>; this version posted May 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






**B****C****D**


Figure 1

A

Spike overlapping peptide pools



B



C




Figure 2




Figure 3

2-3 mths post-vaccination

medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275616>; this version posted May 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 4




Figure 5

A

medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275616>; this version posted May 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




**B****C**

Figure 6







A**B****C**

Figure 7







Peptide Number	A.A Sequence	A.A Position	Peptide Pool	
SP_1	MFVFLVLLPLVSSQC	1-15		Spike pool 1
SP_2	VLLPLVSSQCVNLTT	6-20		Spike pool 1
SP_3	VSSQCVNLTRTQLP	11-25		Spike pool 1
SP_4	VNLTRTQLPPAYTN	16-30		Spike pool 1
SP_5	RTQLPPAYTNSFTRG	21-35		Spike pool 1
SP_6	PAYTNSFTRGVVYPD	26-40		Spike pool 1
SP_7	SFTRGVYYPDKVFRS	31-45		Spike pool 1
SP_8	VYYPDKVFRSSVLHS	36-50		Spike pool 1
SP_9	KVFRSSVLHSTQDLF	41-55		Spike pool 1
SP_10	SVLHSTQDLFLPFFS	46-60		Spike pool 1
SP_11	TQDLFLPFFSNVTWF	51-65		Spike pool 1
SP_12	LPFFSNVTWFHAIHV	56-70		Spike pool 1
SP_13	NVTWFHAIHVSQTNG	61-75		Spike pool 1
SP_14	HAIHVSQTNGTKRFD	66-80		Spike pool 1
SP_15	SGTNGTKRFDNPVLP	71-85		Spike pool 1
SP_16	TKRFDNPVLPFNDGV	76-90		Spike pool 1
SP_17	NPVLPFNDGVYFAST	81-95		Spike pool 1
SP_18	FNDGVYFASTKSNI	86-100		Spike pool 1
SP_19	YFASTKSNIIRGWI	91-105		Spike pool 1
SP_20	EKSNIIRGWIFGTTL	96-110		Spike pool 1
SP_21	IRGWIFGTTLDSKTQ	101-115	Spike gold	Spike pool 1
SP_22	FGTTLDSKTQSLIV	106-120	Spike gold	Spike pool 1
SP_23	DSKTQSLIVNNATN	111-125		Spike pool 1
SP_24	SLIVNNATNVVIKV	116-130		Spike pool 1
SP_25	NNATNVVIKVCEQF	121-135		Spike pool 1
SP_26	VVIKVCEQFCNDPF	126-140		Spike pool 1
SP_27	CEQFCNDPFLGVYY	131-145		Spike pool 1
SP_28	CNDPFLGVYYHKNK	136-150		Spike pool 1
SP_29	LGVYYHKNKSWMES	141-155		Spike pool 1
SP_30	HKNKSWMESEFRVY	146-160		Spike pool 1
SP_31	SWMESEFRVYSSANN	151-165		Spike pool 1
SP_32	EFRVYSSANNCTFEY	156-170		Spike pool 1
SP_33	SSANNCTFEYVSQPF	161-175		Spike pool 1
SP_34	CTFEYVSQPFLMDLE	166-180	Spike gold	Spike pool 1
SP_35	VSQPFLMDLEGKQGN	171-185	Spike gold	Spike pool 2
SP_36	LMDLEGKQGNFKNLR	176-190		Spike pool 2
SP_37	GKQGNFKNLREFVFK	181-195		Spike pool 2
SP_38	FKNLREFVFKNIDGY	186-200		Spike pool 2
SP_39	EFVFKNIDGYFKIYS	191-205		Spike pool 2
SP_40	NIDGYFKIYSKHTPI	196-210		Spike pool 2
SP_41	FKIYSKHTPINLVRD	201-215		Spike pool 2
SP_42	KHTPINLVRDLPQGF	206-220		Spike pool 2
SP_43	NLVRDLPQGFSALEP	211-225		Spike pool 2
SP_44	LPQGFSALEPLVDLP	216-230		Spike pool 2
SP_45	SALEPLVDLPIGINI	221-235		Spike pool 2

SP_46	LVDLPIGINITRFQT	226-240		Spike pool 2
SP_47	IGINITRFQTLALH	231-245		Spike pool 2
SP_48	TRFQTLALHRSYLT	236-250	Spike gold	Spike pool 2
SP_49	LLALHRSYLTPGDSS	241-255	Spike gold	Spike pool 2
SP_50	RSYLTPGDSSSGWTA	246-260	Spike gold	Spike pool 2
SP_51	PGDSSSGWTAGAAAY	251-265		Spike pool 2
SP_52	SGWTAGAAAYVGYL	256-270		Spike pool 2
SP_53	GAAAYVGYLQPRTF	261-275		Spike pool 2
SP_54	YVGYLQPRTFLLKYN	266-280		Spike pool 2
SP_55	QPRTFLLKYNENGTI	271-285		Spike pool 2
SP_56	LLKYNENGTITDAVD	276-290		Spike pool 2
SP_57	ENGTITDAVDCALDP	281-295		Spike pool 2
SP_58	TDAVDCALDPLSETK	286-300		Spike pool 2
SP_59	CALDPLSETKCTLS	291-305	Spike gold	Spike pool 2
SP_60	LSETKCTLSFTVEK	296-310	Spike gold	Spike pool 2
SP_61	CTLSFTVEKGIYQT	301-315	Spike gold	Spike pool 2
SP_62	FTVEKGIYQTSNFRV	306-320	Spike gold	Spike pool 2
SP_63	GIYQTSNFRVQPTES	311-325	Spike gold	Spike pool 2
SP_64	SNFRVQPTESIVRFP	316-330		Spike pool 2
SP_65	QPTESIVRFPNITNL	321-335		Spike pool 2
SP_66	IVRFPNITNLCPFGE	326-340		Spike pool 2
SP_67	NITNLCPFGEVFNAT	331-345		Spike pool 2
SP_68	CPFGEVFNATRFASV	336-350		Spike pool 3
SP_69	VFNATRFASVYAWNR	341-355		Spike pool 3
SP_70	RFASVYAWNRKRISN	346-360		Spike pool 3
SP_71	YAWNRKRISNCVADY	351-365		Spike pool 3
SP_72	KRISNCVADYSVLYN	356-370		Spike pool 3
SP_73	CVADYSVLYNSASF	361-375		Spike pool 3
SP_74	SVLYNSASFSTFKCY	366-380		Spike pool 3
SP_75	SASFSTFKCYGVSPT	371-385	Spike gold	Spike pool 3
SP_76	TFKCYGVSPTKLNDL	376-390	Spike gold	Spike pool 3
SP_77	GVSPTKLNDLCFTNV	381-395		Spike pool 3
SP_78	KLNDLCFTNVYADSF	386-400		Spike pool 3
SP_79	CFTNVYADSFVIRGD	391-405		Spike pool 3
SP_80	YADSFVIRGDEVQRQI	396-410		Spike pool 3
SP_81	VIRGDEVQRQIAPGQT	401-415		Spike pool 3
SP_82	EVRQIAPGQTGKIAD	406-420		Spike pool 3
SP_83	APGQTGKIADYNYKL	411-425		Spike pool 3
SP_84	GKIADYNYKLPPDFT	416-430		Spike pool 3
SP_85	YNYKLPPDFTGCVIA	421-435	Spike gold	Spike pool 3
SP_86	PDDFTGCVIAWNSNN	426-440		Spike pool 3
SP_87	GCVIAWNSNNLDSKV	431-445		Spike pool 3
SP_88	WNSNNLDSKVGGNYN	436-450	Spike gold	Spike pool 3
SP_89	LDSKVGGNYNLYRL	441-455	Spike gold	Spike pool 3
SP_90	GGNYNLYRLFRKSN	446-460	Spike gold	Spike pool 3
SP_91	YLYRLFRKSNLKPFE	451-465	Spike gold	Spike pool 3

SP_92	FRKSNLKPFERDIST	456-470	Spike gold	Spike pool 3
SP_93	LKPFERDISTEIYQA	461-475	Spike gold	Spike pool 3
SP_94	RDISTEIYQAGSTPC	466-480		Spike pool 3
SP_95	EIYQAGSTPCNGVEG	471-485		Spike pool 3
SP_96	GSTPCNGVEGFNCYF	476-490		Spike pool 3
SP_97	NGVEGFNCYFPLQSY	481-495		Spike pool 3
SP_98	FNCYFPLQSYGFQPT	486-500		Spike pool 3
SP_99	PLQSYGFQPTNGVGY	491-505		Spike pool 3
SP_100	GFQPTNGVGYQPYRV	496-510		Spike pool 3
SP_101	NGVGYQPYRVVLSF	501-515		Spike pool 4
SP_102	QPYRVVLSFELLHA	506-520		Spike pool 4
SP_103	VVLSFELLHAPATVC	511-525		Spike pool 4
SP_104	ELLHAPATVCGPKKS	516-530		Spike pool 4
SP_105	PATVCGPKKSTNLVK	521-535		Spike pool 4
SP_106	GPKKSTNLVKNKCVN	526-540	Spike gold	Spike pool 4
SP_107	TNLVKNKCVNFNFNG	531-545	Spike gold	Spike pool 4
SP_108	NKCVNFNFNGLTGTG	536-550		Spike pool 4
SP_109	FNFNGLTGTGVLTES	541-555	Spike gold	Spike pool 4
SP_110	LTGTGVLTESNKKFL	546-560	Spike gold	Spike pool 4
SP_111	VLTESNKKFLPFQQF	551-565		Spike pool 4
SP_112	NKKFLPFQQFGRDIA	556-570		Spike pool 4
SP_113	PFQQFGRDIADTTDA	561-575		Spike pool 4
SP_114	GRDIADTTDAVRDPQ	566-580		Spike pool 4
SP_115	DTTDAVRDPQTLEIL	571-585		Spike pool 4
SP_116	VRDPQTLEILDITPC	576-590		Spike pool 4
SP_117	TLEILDITPCSFGGV	581-595		Spike pool 4
SP_118	DITPCSFGGVSVITP	586-600		Spike pool 4
SP_119	SFGGVSVITPGTNTS	591-605		Spike pool 4
SP_120	SVITPGTNTSNQVAV	596-610		Spike pool 4
SP_121	GTNTSNQVAVLYQDV	601-615		Spike pool 4
SP_122	NQVAVLYQDVNCTEV	606-620		Spike pool 4
SP_123	LYQDVNCTEVPVAIH	611-625		Spike pool 4
SP_124	NCTEVPVAIHADQLT	616-630		Spike pool 4
SP_125	PVAIHADQLTPTWRV	621-635		Spike pool 4
SP_126	ADQLTPTWRVYSTGS	626-640		Spike pool 4
SP_127	PTWRVYSTGSNVFQT	631-645		Spike pool 4
SP_128	YSTGSNVFQTRAGCL	636-650		Spike pool 4
SP_129	NVFQTRAGCLIGAEH	641-655		Spike pool 4
SP_130	RAGCLIGAEHVNNSY	646-660	Spike gold	Spike pool 4
SP_131	IGAEHVNNSYECDIP	651-665	Spike gold	Spike pool 4
SP_132	VNNSYECDIPIGAGI	656-670		Spike pool 4
SP_133	ECDIPIGAGICASYQ	661-675		Spike pool 4
SP_134	IGAGICASYQTQTNS	666-680		Spike pool 4
SP_135	CASYQTQTNSPRRAR	671-685		Spike pool 4
SP_136	TQTNSPRRARSVASQ	676-690		Spike pool 4
SP_137	PRRARSVASQSIIAY	681-695		Spike pool 4

SP_138	SVASQSIAYTMSLG	686-700	Spike gold	Spike pool 4
SP_139	SIIAYTMSLGAENSV	691-705	Spike gold	Spike pool 4
SP_140	TMSLGAENSVAYSNN	696-710	Spike gold	Spike pool 5
SP_141	AENSVAYSNNIAIP	701-715		Spike pool 5
SP_142	AYSNNSIAIPTNFTI	706-720		Spike pool 5
SP_143	SIAIPTNFTISVTTE	711-725		Spike pool 5
SP_144	TNFTISVTTEILPVS	716-730		Spike pool 5
SP_145	SVTTEILPVSMTKTS	721-735		Spike pool 5
SP_146	ILPVSMTKTSVDCTM	726-740		Spike pool 5
SP_147	MTKTSVDCTMYICGD	731-745		Spike pool 5
SP_148	VDCTMYICGDSTEC	736-750		Spike pool 5
SP_149	YICGDSTECNLLQ	741-755		Spike pool 5
SP_150	STECNLLQYGSFC	746-760	Spike gold	Spike pool 5
SP_151	NLLQYGSFCTQLNR	751-765	Spike gold	Spike pool 5
SP_152	YGSFCTQLNRALTGI	756-770		Spike pool 5
SP_153	TQLNRALTGIAVEQD	761-775		Spike pool 5
SP_154	ALTGIAVEQDKNTQE	766-780		Spike pool 5
SP_155	AVEQDKNTQEVFAQV	771-785		Spike pool 5
SP_156	KNTQEVFAQVKQIYK	776-790	Spike gold	Spike pool 5
SP_157	VFAQVKQIYKTPPIK	781-795	Spike gold	Spike pool 5
SP_158	KQIYKTPPIKDFGGF	786-800	Spike gold	Spike pool 5
SP_159	TPPIKDFGGFNFSQI	791-805	Spike gold	Spike pool 5
SP_160	DFGGFNFSQILPDPS	796-810		Spike pool 5
SP_161	NFSQILPDPSKPSKR	801-815	Spike gold	Spike pool 5
SP_162	LPDPSKPSKRSFIED	806-820		Spike pool 5
SP_163	KPSKRSFIEDLLFNK	811-825		Spike pool 5
SP_164	SFIEDLLFNKVTLAD	816-830		Spike pool 5
SP_165	LLFNKVTLADAGFIK	821-835		Spike pool 5
SP_166	VTLADAGFIKQYGDC	826-840		Spike pool 5
SP_167	AGFIKQYGDCLGDIA	831-845	Spike gold	Spike pool 5
SP_168	QYGDCLGDIAARDLI	836-850	Spike gold	Spike pool 5
SP_169	LGDIAARDLICAQKF	841-855		Spike pool 5
SP_170	ARDLICAQKFNGLTV	846-860		Spike pool 5
SP_171	CAQKFNGLTVLPPL	851-865		Spike pool 5
SP_172	NGLTVLPPLTDEMI	856-870		Spike pool 5
SP_173	LPPLTDEMIAQYTS	861-875		Spike pool 5
SP_174	TDEMIAQYTSALLAG	866-880		Spike pool 5
SP_175	AQYTSALLAGTITSG	871-885		Spike pool 5
SP_176	ALLAGTITSGWTFGA	876-890		Spike pool 5
SP_177	TITSGWTFGAGAAALQ	881-895		Spike pool 5
SP_178	WTFGAGAAALQIPFAM	886-900		Spike pool 6
SP_179	GAALQIPFAMQMAYR	891-905	Spike gold	Spike pool 6
SP_180	IPFAMQMAYRFNGIG	896-910		Spike pool 6
SP_181	QMAYRFNGIGVTQNV	901-915	Spike gold	Spike pool 6
SP_182	FNGIGVTQNVLYENQ	906-920	Spike gold	Spike pool 6
SP_183	VTQNVLYENQKLIAN	911-925		Spike pool 6

SP_184	LYENQKLIANQFNSA	916-930		Spike pool 6
SP_185	KLIANQFNSAIGKIQ	921-935		Spike pool 6
SP_186	QFNSAIGKIQDSLSS	926-940		Spike pool 6
SP_187	IGKIQDSLSTASAL	931-945		Spike pool 6
SP_188	DSLSTASALGKLQD	936-950	Spike gold	Spike pool 6
SP_189	TASALGKLQDVVNQN	941-955	Spike gold	Spike pool 6
SP_190	GKLQDVVNQNAQALN	946-960		Spike pool 6
SP_191	VVNQNAQALNTLVKQ	951-965		Spike pool 6
SP_192	AQALNTLVKQLSSNF	956-970	Spike gold	Spike pool 6
SP_193	TLVKQLSSNFGAISS	961-975		Spike pool 6
SP_194	LSSNFGAISSVLNDI	966-980		Spike pool 6
SP_195	GAISSVLNDILSRLD	971-985		Spike pool 6
SP_196	VLNDILSRLDKVEAE	976-990	Spike gold	Spike pool 6
SP_197	LSRLDKVEAEVQIDR	981-995		Spike pool 6
SP_198	KVEAEVQIDRLITGR	986-1000		Spike pool 6
SP_199	VQIDRLITGRLQSLQ	991-1005		Spike pool 6
SP_200	LITGRLQSLQTYVTQ	996-1010	Spike gold	Spike pool 6
SP_201	LQSLQTYVTQQLIRA	1001-1015		Spike pool 6
SP_202	TYVTQQLIRAAEIRA	1006-1020		Spike pool 6
SP_203	QLIRAAEIRASANLA	1011-1025	Spike gold	Spike pool 6
SP_204	AEIRASANLAATKMS	1016-1030	Spike gold	Spike pool 6
SP_205	SANLAATKMSECVLG	1021-1035		Spike pool 6
SP_206	ATKMSECVLGQSKRV	1026-1040		Spike pool 6
SP_207	ECVLGQSKRVDFCGK	1031-1045		Spike pool 6
SP_208	QSKRVDFCGKGYHLM	1036-1050		Spike pool 6
SP_209	DFCGKGYHLMSFPQS	1041-1055		Spike pool 6
SP_210	GYHLMSFPQSAPHGV	1046-1060		Spike pool 6
SP_211	SFPQSAPHGVVFLHV	1051-1065		Spike pool 6
SP_212	APHGVVFLHVTVVPA	1056-1070	Spike gold	Spike pool 6
SP_213	VFLHVTVVPAQEKNF	1061-1075		Spike pool 6
SP_214	TVVPAQEKNFTTAPA	1066-1080		Spike pool 6
SP_215	QEKNFTTAPAICHDG	1071-1085		Spike pool 6
SP_216	TTAPAICHDGKAHFP	1076-1090		Spike pool 7
SP_217	ICHDGKAHFPREGVF	1081-1095		Spike pool 7
SP_218	KAHFPREGVFVSNGT	1086-1100		Spike pool 7
SP_219	REGVFVSNGTHWFVT	1091-1105		Spike pool 7
SP_220	VSNGTHWFVTQRNFY	1096-1110		Spike pool 7
SP_221	HWFVTQRNFYEPQII	1101-1115	Spike gold	Spike pool 7
SP_222	QRNFYEPQIITDNT	1106-1120		Spike pool 7
SP_223	EPQIITDNTFVSGN	1111-1125		Spike pool 7
SP_224	TTDNTFVSGNCDVVI	1116-1130		Spike pool 7
SP_225	FVSGNCDVVIGIVNN	1121-1135		Spike pool 7
SP_226	CDVVIGIVNNTVYDP	1126-1140		Spike pool 7
SP_227	GIVNNTVYDPLQPEL	1131-1145		Spike pool 7
SP_228	TVYDPLQPELDSFKE	1136-1150		Spike pool 7
SP_229	LQPELDSFKEELDKY	1141-1155		Spike pool 7

SP_230	DSFKEELDKYFKNHT	1146-1160		Spike pool 7
SP_231	ELDKYFKNHTSPDVD	1151-1165		Spike pool 7
SP_232	FKNHTSPDVDLGDIS	1156-1170		Spike pool 7
SP_233	SPDVDLGDISGINAS	1161-1175		Spike pool 7
SP_234	LGDISGINASVVNIQ	1166-1180		Spike pool 7
SP_235	GINASVVNIQKEIDR	1171-1185		Spike pool 7
SP_236	VVNIQKEIDRLNEVA	1176-1190		Spike pool 7
SP_237	KEIDRLNEVAKNLNE	1181-1195	Spike gold	Spike pool 7
SP_238	LNEVAKNLNESLIDL	1186-1200	Spike gold	Spike pool 7
SP_239	KNLNESLIDLQELGK	1191-1205	Spike gold	Spike pool 7
SP_240	SLIDLQELGKYEQYI	1196-1210		Spike pool 7
SP_241	QELGKYEQYIKWPWY	1201-1215		Spike pool 7
SP_242	YEQYIKWPWYIWLGF	1206-1220		Spike pool 7
SP_243	KWPWYIWLGFIAGLI	1211-1225		Spike pool 7
SP_244	IWLGFIAGLIAIVMV	1216-1230	Spike gold	Spike pool 7
SP_245	IAGLIAIVMVTIMLC	1221-1235		Spike pool 7
SP_246	AIVMVTIMLCCMTSC	1226-1240		Spike pool 7
SP_247	TIMLCCMTSCCCLK	1231-1245		Spike pool 7
SP_248	CMTSCCCLKGCCSC	1236-1250		Spike pool 7
SP_249	CCLKGCCSCGSCCK	1241-1255		Spike pool 7
SP_250	GCCSCGSCCKFDEDD	1246-1260		Spike pool 7
SP_251	GSCCKFDEDDSEPV	1251-1265		Spike pool 7
SP_252	FDEDDSEPVKGVKL	1256-1270		Spike pool 7
SP_253	SEPVKGVKLHYT	1261-1273		Spike pool 7

Peptide Number	A.A Sequence	A.A Position	Peptide pool
M_1	MADSNGTITVEELKK	1-15	M
M_2	GTITVEELKKLLEQW	6-20	M
M_3	EELKKLLEQWNLVIG	11-25	M
M_4	LLEQWNLVIGFLFLT	16-30	M
M_5	NLVIGFLFLTWICLL	21-35	M
M_6	FLFLTWICLLQFAYA	26-40	M
M_7	WICLLQFAYANRRNF	31-45	M
M_8	QFAYANRRNFLYIIK	36-50	M
M_9	NRNFLYIIKLIFLW	41-55	M
M_10	LYIIKLIFLWLLWPV	46-60	M
M_11	LIFLWLLWPVTLACF	51-65	M
M_12	LLWPVTLACFVLA AV	56-70	M
M_13	TLACFVLA AVYRINW	61-75	M
M_14	VLA AVYRINWITGGI	66-80	M
M_15	YRINWITGGIAIAMA	71-85	M
M_16	ITGGIAIAMA CLVGL	76-90	M
M_17	AIAMA CLVGLMWLSY	81-95	M
M_18	CLVGLMWLSYFIASF	86-100	M
M_19	MWLSYFIASFRLFAR	91-105	M
M_20	FIASFRLFARTRSMW	96-110	M
M_21	RLFARTRSMW SFNPE	101-115	M
M_22	TRSMW SFNPETNILL	106-120	M
M_23	SFNPETNILLNVPLH	111-125	M
M_24	TNILLNVPLHGTILT	116-130	M
M_25	NVPLHGTILTRP LLE	121-135	M
M_26	GTILTRP LLESELVI	126-140	M
M_27	RP LLESELVIGAVIL	131-145	M
M_28	SELVIGAVILRGHLR	136-150	M
M_29	GAVILRGHLRIAGHH	141-155	M
M_30	RGHLRIAGHH LGRCD	146-160	M
M_31	IAGHH LGRCDIKDLP	151-165	M
M_32	LGRCDIKDLPKEITV	156-170	M
M_33	IKDLPKEITVATSRT	161-175	M
M_34	KEITVATSRTL SYYK	166-180	M
M_35	ATSRTL SYYKLGASQ	171-185	M
M_36	LSYYKLGASQRVAGD	176-190	M
M_37	LGASQRVAGDSGFAA	181-195	M
M_38	RVAGDSGFAA SRYR	186-200	M
M_39	SGFAA SRYRIGNYK	191-205	M
M_40	YSRYRIGNYKLNTDH	196-210	M
M_41	IGNYKLNTDHSSSSD	201-215	M
M_42	LNTDHSSSSDNIALL	206-220	M
M_43	SSSSDNIALLVQ	211-222	M

Peptide Number	A.A Sequence	A.A Position	Peptide Pool
NP_1	MSDNGPQNQRNAPRI	1-15	NP1
NP_2	PQNQRNAPRITFGGP	6-20	NP1
NP_3	NAPRITFGG PSDSTG	11-25	NP1
NP_4	TFGG PSDSTGSNQNG	16-30	NP1
NP_5	SDSTGSNQNGERSGA	21-35	NP1
NP_6	SNQNGERSGARSKQR	26-40	NP1
NP_7	ERSGARSKQRRPQGL	31-45	NP1
NP_8	RSKQRRPQGLPNNTA	36-50	NP1
NP_9	RPQGLPNNTASWFTA	41-55	NP1
NP_10	PNNTASWFTALTQHG	46-60	NP1
NP_11	SWFTALTQHGKEDLK	51-65	NP1
NP_12	LTQHGKEDLKFPRGQ	56-70	NP1
NP_13	KEDLKFPRGQGV PIN	61-75	NP1
NP_14	FPRGQGV PINTNSSP	66-80	NP1
NP_15	GV PINTNSSPDDQIG	71-85	NP1
NP_16	TNSSPDDQIGYYRRA	76-90	NP1
NP_17	DDQIGYYRRATRRIR	81-95	NP1
NP_18	YYRRATRRIRGGDGK	86-100	NP1
NP_19	TRRIRGGDGKMKDLS	91-105	NP1
NP_20	GGDGKMKDLSPRWYF	96-110	NP1
NP_21	MKDLSPRWYFY YLGT	101-115	NP1
NP_22	PRWYFY YLGTGPEAG	106-120	NP1
NP_23	YYLGTGPEAGLPYGA	111-125	NP1
NP_24	GPEAGLPYGANKDGI	116-130	NP1
NP_25	LPYGANKDGIWVAT	121-135	NP1
NP_26	NKDGIWVATEGALN	126-140	NP1
NP_27	IWVATEGALNTPKDH	131-145	NP1
NP_28	EGALNTPKDHIGTRN	136-150	NP1
NP_29	TPKDHIGTRNPANNA	141-155	NP1
NP_30	IGTRNPANNAIVLQ	146-160	NP1
NP_31	PANNAIVLQLPQGT	151-165	NP1
NP_32	AIVLQLPQGTTLPKG	156-170	NP1
NP_33	LPQGTTL PKGFYAEG	161-175	NP1
NP_34	TLPKGFYAEGSRGGS	166-180	NP1
NP_35	FYAEGSRGGSQASSR	171-185	NP1
NP_36	SRGGSQASSRSSRS	176-190	NP1
NP_37	QASSRSSRSRNSSR	181-195	NP1
NP_38	SSRSRNSSRNSTPG	186-200	NP1
NP_39	RNSSRNSTPGSSRGT	191-205	NP1
NP_40	NSTPGSSRGTSPARM	196-210	NP1
NP_41	SSRGTSPARMAGNGG	201-215	NP1
NP_42	SPARMAGNGGDAALA	206-220	NP2
NP_43	AGNGGDAALALLLD	211-225	NP2
NP_44	DAALALLLDRLNQL	216-230	NP2
NP_45	LLLDRLNQLESKMS	221-235	NP2

NP_46	RLNQLESKMSGKGQQ	226-240	NP2
NP_47	ESKMSGKGQQQQGQT	231-245	NP2
NP_48	GKGQQQQGQTVTKKS	236-250	NP2
NP_49	QQGQTVTKKSAAEAS	241-255	NP2
NP_50	VTKKSAAEASKKPRQ	246-260	NP2
NP_51	AAEASKKPRQKRTAT	251-265	NP2
NP_52	KKPRQKRTATKAYNV	256-270	NP2
NP_53	KRTATKAYNVTQAFG	261-275	NP2
NP_54	KAYNVTQAFGRRGPE	266-280	NP2
NP_55	TQAFGRRGPEQTQGN	271-285	NP2
NP_56	RRGPEQTQGNFGDQE	276-290	NP2
NP_57	QTQGNFGDQELIRQG	281-295	NP2
NP_58	FGDQELIRQGTDYKH	286-300	NP2
NP_59	LIRQGTDYKHWPQIA	291-305	NP2
NP_60	TDYKHWPQIAQFAPS	296-310	NP2
NP_61	WPQIAQFAPSASAFF	301-315	NP2
NP_62	QFAPSASAFFGMSRI	306-320	NP2
NP_63	ASAFFGMSRIGMEVT	311-325	NP2
NP_64	GMSRIGMEVTPSGTW	316-330	NP2
NP_65	GMEVTPSGTWLTYTG	321-335	NP2
NP_66	PSGTWLTGTGAIKLD	326-340	NP2
NP_67	LTYTGAIKLDDKDPN	331-345	NP2
NP_68	AIKLDDKDPNFKDQV	336-350	NP2
NP_69	DKDPNFKDQVILLNK	341-355	NP2
NP_70	FKDQVILLNKHIDAY	346-360	NP2
NP_71	ILLNKHIDAYKTFPP	351-365	NP2
NP_72	HIDAYKTFPPTPKK	356-370	NP2
NP_73	KTFPPTPKKDKKKK	361-375	NP2
NP_74	TEPKKDKKKKADETQ	366-380	NP2
NP_75	DKKKKADETQALPQR	371-385	NP2
NP_76	ADETQALPQRQKKQQ	376-390	NP2
NP_77	ALPQRQKKQQVTLL	381-395	NP2
NP_78	QKKQQVTLLPAADL	386-400	NP2
NP_79	TVTLLPAADLDDFSK	391-405	NP2
NP_80	PAADLDDFSKQLQQS	396-410	NP2
NP_81	DDFSKQLQQSMSSAD	401-415	NP2
NP_82	QLQQSMSSADSTQA	406-419	NP2

Protein	Peptide Number(Ancestral)	Ancestral A.A Position	Mutation	Ancestral A.A Sequence	Variant A.A Sequence
Spike	SP_12	56-70	A67V/DEL69-70	LPFFSNVTWFHAIHV	LPFFSNVTWFHVISG
Spike	SP_13	61-75	A67V/DEL69-70	NVTWFHAIHVSNGTNG	NVTWFHVISGNTGK
Spike	SP_14	66-80	A67V/DEL69-70	HAIHVSNGTNGTKRFD	HVISGNTGTKRFDNP
Spike	SP_17	81-95	T95I	NPVLPFNDGVYFAST	NPVLPFNDGVYFASI
Spike	SP_18	86-100	T95I	FNDGVYFASTEKSN	FNDGVYFASIEKSN
Spike	SP_19	91-105	T95I	YFASTEKSNIRGWI	YFASIEKSNIRGWI
Spike	SP_27	131-145	G142D/DEL143-145	CEQFCNDPFLGVYY	CEQFCNDPFLDHKN
Spike	SP_28	136-150	G142D/DEL143-145	CNDPFLGVYYHKNNK	CNDPFLDHKNNKSWM
Spike	SP_29	141-155	G142D/DEL143-145	LGVYYHKNNKSWMES	LDHKNNKSWMESEFR
Spike	SP_41	201-215	N211I/DEL212/ins214EPE	FKIYSKHTPINLVRD	FKIYSKHTPIIVEPE
Spike	SP_42	206-220	N211I/DEL212/ins214EPE	KHTPINLVRDLRDLQGF	KHTPIIVEPERDLRDLQ
Spike	SP_43	211-225	N211I/DEL212/ins214EPE	NLVRDLRDLRDLQGFSALEP	IVEPERDLRDLRDLQGFSALEP
Spike	SP_66	326-340	G339D	IVRFPNITNLCPFGE	IVRFPNITNLCPFDE
Spike	SP_67	331-345	G339D	NITNLCPFGEVFNAT	NITNLCPFDEVFNAT
Spike	SP_68	336-350	G339D	CPFGEVFNATRFASV	CPFDEVFNATRFASV
Spike	SP_73	361-375	S371L/S373P/S375F	CVADYSVLVNSASF	CVADYSVLVNLAPFF
Spike	SP_74	366-380	S371L/S373P/S375F	SVLVNSASFSTFKCY	SVLVNLAPFFSTFKCY
Spike	SP_75	371-385	S371L/S373P/S375F	SASFSTFKCYGVSP	LAPFFSTFKCYGVSP
Spike	SP_82	406-420	K417N	EVRQIAPGQTGKIAD	EVRQIAPGQTGNIA
Spike	SP_83	411-425	K417N	APGQTGKIADYNYKL	APGQTGNIAADYNYKL
Spike	SP_84	416-430	K417N	GKIADYNYKLPPDFT	GNIAADYNYKLPPDFT
Spike	SP_86	426-440	N440K	PDDFTGCVIAWNSNN	PDDFTGCVIAWNSNK
Spike	SP_87	431-445	N440K	GCVIAWNSNNLDSKV	GCVIAWNSNKLDSKV
Spike	SP_88	436-450	N440K/G446S	WNSNNLDSKVGNGYN	WNSNKLDSKVSNGYN
Spike	SP_89	441-455	G446S	LDSKVGNGYNYLRL	LDSKVSNGYNYLRL
Spike	SP_90	446-460	G446S	GGNYNYLRLFRKSN	SGNYNYLRLFRKSN
Spike	SP_94	466-480	S477N/T478K	RDISTEIQAGSTPC	RDISTEIQAGNKPC
Spike	SP_95	471-485	S477N/T478K/E484A	EIQAGSTPCNGVEG	EIQAGNKPCNGVAG
Spike	SP_96	476-490	S477N/T478K/E484A	GSTPCNGVEGFNCYF	GNKPCNGVAGFNCFY
Spike	SP_97	481-495	E484A/Q493R/	NGVEGFNCYFPLQSY	NGVAGFNCFYPLRSY
Spike	SP_98	486-500	Q493R/G496S/Q498R	FNCYFPLQSYGFQPT	FNCYFPLRSYSFRPT
Spike	SP_99	491-505	Q493R/G496S/Q498R/N501Y/Y505H	PLQSYGFQPTNGVGY	PLRSYSFRPTYGVGH
Spike	SP_100	496-510	G496S/Q498R/N501Y/Y505H	GFQPTNGVGYQPYRV	SFRPTYGVGHQPYRV
Spike	SP_101	501-515	N501Y/Y505H	NGVGYQPYRVVLSF	YGVGHQPYRVVLSF
Spike	SP_108	536-550	T547K	NKCVNFNFLGTGTG	NKCVNFNFLKGTGTG
Spike	SP_109	541-555	T547K	FNFNLTGTGVLTE	FNFNLTGTGVLTE
Spike	SP_110	546-560	T547K	LTGTGVLTESNKFL	LKGTGVLTESNKFL
Spike	SP_121	601-615	D614G	GTNTSNQVAVLYQDV	GTNTSNQVAVLYQGV
Spike	SP_122	606-620	D614G	NQVAVLYQDVNCTEV	NQVAVLYQGVNCTEV
Spike	SP_123	611-625	D614G	LYQDVNCTEVPVAIH	LYQGVNCTEVPVAIH
Spike	SP_129	641-655	H655Y	NVFQTRAGCLIGAEH	NVFQTRAGCLIGAEY
Spike	SP_130	646-660	H655Y	RAGCLIGAEHVNSY	RAGCLIGAEYVNSY
Spike	SP_131	651-665	H655Y	IGAEHVNSYECIDIP	IGAEYVNSYECIDIP
Spike	SP_134	666-680	N679K	IGAGICASYQTQNS	IGAGICASYQTQKS
Spike	SP_135	671-685	N679K/P681H	CASYQTQNSPRRAR	CASYQTQTKSHRRAR
Spike	SP_136	676-690	N679K/P681H	TQTNSPRRARSVASQ	TQTKSHRRARSVASQ
Spike	SP_137	681-695	P681H	PRRARSVASQSIAY	HRRARSVASQSIAY
Spike	SP_140	696-710	A701V	TMSLGAENSVAYSNN	TMSLGVENSVAYSNN
Spike	SP_141	701-715	A701V	AENSVAYSNNSIAIP	VENSVAYSNNSIAIP
Spike	SP_151	751-765	N764K	NLLQYGSFCTQLNR	NLLQYGSFCTQLKR
Spike	SP_152	756-770	N764K	YGSFCTQLNRALTGI	YGSFCTQLKRALTGI
Spike	SP_153	761-775	N764K	TQLNRALTGIAVEQD	TQLKRALTGIAVEQD
Spike	SP_158	786-800	D796Y	KQIYKTPPIKDFGGF	KQIYKTPPIKYFGGF
Spike	SP_159	791-805	D796Y	TPPIKDFGGFNFSQI	TPPIKYFGGFNFSQI
Spike	SP_160	796-810	D796Y	DFGGFNFSQILPDP	YFGGFNFSQILPDP

Spike	SP_170	846-860	N856K	ARDLICAQKFNGLTV	ARDLICAQKF K GLTV
Spike	SP_171	851-865	N856K	CAQKFNGLTVLPPLL	CAQKF K GLTVLPPLL
Spike	SP_172	856-870	N856K	NGLTVLPPLLTDEMI	K GLTVLPPLLTDEMI
Spike	SP_189	941-955	Q954H	TASALGKLQDVVNQN	TASALGKLQDVVN H N
Spike	SP_190	946-960	Q954H	GKLQDVVNQNAQALN	GKLQDVVN H NAQALN
Spike	SP_191	951-965	Q954H	VVNQNAQALNTLVKQ	VVN H NAQALNTLVKQ
Spike	SP_192	956-970	N969K	AQALNTLVKQLSSNF	AQALNTLVKQL S KF
Spike	SP_193	961-975	N969K	TLVKQLSSNFGAISS	TLVKQL S KFGAISS
Spike	SP_194	966-980	N969K	LSSNFGAISSVLNDI	L S S K FGAISSVLNDI
Spike	SP_195	971-985	L981F	GAISSVLNDILSRLD	GAISSVLNDI F SRLD
Spike	SP_196	976-990	L981F	VLNDILSRLDKVEAE	VLNDI F SRLDKVEAE
Spike	SP_197	981-995	L981F	LSRLDKVEAEVQIDR	F SRLDKVEAEVQIDR
Membrane	M1	1-15	D3G	MADSNGTITVEELK	MAG S NGTITVEELK
Membrane	M2	6-20	Q19E	GTITVEELKLE	GTITVEELKLE Q W E W
Membrane	M3	11-25	Q19E	EELKLE	Q W NLVIG E WNLVIG
Membrane	M4	16-30	Q19E	LLE	Q W NLVIGFLFT E WNLVIGFLFT
Membrane	M11	51-65	A63T	LIFLWLLWPVTL	A C F T C F
Membrane	M12	56-70	A63T	LLWPVTL	A C FVLA A V
Membrane	M13	61-75	A63T	TL	A C FVLA A VYRIN W
Nucleoprotein	NP1	1-15	P13L	MSDNGPQNQRNAPRI	MSDNGPQNQRN A LRI
Nucleoprotein	NP2	6-20	P13L	PQNQRNAPRITFGGP	PQNQRN A LRI T FGGP
Nucleoprotein	NP3	11-25	P13L	NAPRITFGGPSDSTG	N A L RITFGGPSDSTG
Nucleoprotein	NP5	21-35	DEL31-33	SDSTGSNQNG	E R S G A SDSTGSNQNG G A R S K
Nucleoprotein	NP6	26-40	DEL31-33	SNQNG	E R S G A R S K Q R SNQNG G A R S K Q R P Q
Nucleoprotein	NP7	31-45	DEL31-33	E R S G A R S K Q R R P Q G L	G A R S K Q R R P Q G L P N N
Nucleoprotein	NP39	191-205	R203K/G204R	RNSSRNSTPGSS	R G T RNSSRNSTPGSS K R T
Nucleoprotein	NP40	196-210	R203K/G204R	NSTPGSS	R G T SPARM NSTPGSS K R T SPARM
Nucleoprotein	NP41	201-215	R203K/G204R	SS R G T SPARMAGNGG	S S R G T SPARMAGNGG
Nucleoprotein	NP67	331-345	D343G	LTYTGAIKLDDKDPN	LTYTGAIKLDD K G P N
Nucleoprotein	NP68	336-350	D343G	AIKLDDKDPNFKDQV	AIKLDD K G P N FKDQV
Nucleoprotein	NP69	341-355	D343G	DKDPNFKDQVILLNK	D K G P N FKDQVILLNK